

Databases for RA/QA Professionals



FDA Oncologic Drugs Advisory Committee

Member Biographies and Voting History

ODAC Chair:	Brian I. Rini, M.D., FACP
ODAC Permanent Members:	Alberto S. Pappo, M.D. Alice T. Shaw, M.D., Ph.D. Grzegorz S. Nowakowski, M.D. Heidi D. Klepin, M.D., MS Gregory J. Riely, MD, PhD Philip C. Hoffman, M.D. Susan Halabi, Ph.D. Thomas S. Uldrick, MD, MS Vassiliki A. Papadimitrakopoulou, M.D.
ODAC Patient Rep.:	N/A
ODAC Consumer Rep.:	Courtney J. Preusse, MA
ODAC Industry Rep.:	Phuong Khanh (P.K.) Morrow, M.D., FACP
FDA Designated Federal Official:	Lauren D. Tesh, Pharm.D., BCPS Division of Advisory Committee and Consultant Management

[FDA Temporary Members](#)

Meeting Dates

- [June 20, 2018](#): US FDA Advisory Committee Gives Input on Molecular Targets for Pediatric Cancers and Approaches to Pediatric Drug Development (ODAC) (Pediatric Oncology Subcommittee)
- [March 7, 2018](#): US FDA Advisory Committee Votes in Support of Amgen's Blincyto for Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia (ODAC) - [FDA Decision Report](#)
- [September 19, 2017](#): US FDA Posts Advisory Committee Materials for Amgen's Blincyto for Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia (ODAC) - [FDA Decision Report](#)
- [July 13, 2017](#): US FDA Advisory Committee Supports Proposed Biosimilars of Avastin and Herceptin (ODAC)
- [July 12, 2017](#): US FDA Advisory Committee Unanimously Supports First CAR-T Reviewed by Committee (ODAC) - [FDA Decision Report](#)
- [July 11, 2017](#): US FDA Advisory Committee Nearly Unanimously Supports Pfizer's Mylotarg (ODAC) - [FDA Decision Report](#)
- [June 21-22, 2017](#): US FDA Advisory Committee Reviews Potential Pediatric Written Requests for Cancer Drugs and Candidates (ODAC) (Pediatric Oncology Subcommittee)
- [May 25, 2017](#): US FDA Advisory Committee Almost Unanimously Supports Epoetin Hospira, a Proposed Biosimilar of Amgen's Epogen, by Hospira, a Pfizer Company (ODAC) - [FDA Decision Report](#)
- [May 24, 2017](#): US FDA Advisory Committee Supports Puma Biotechnology's Neratinib for Breast Cancer and Emmaus Medical's L-Glutamine Solution for Sickle Cell Disease (ODAC) - [FDA Decision Report](#)
- [March 29, 2017](#): US FDA Advisory Committee Unanimously Supports Subcutaneous Formulation of Genentech's Rituxan (ODAC) - [FDA Decision Report](#)
- [September 14, 2016](#): US FDA Advisory Committee Unanimously Does Not Support Approval of Spectrum's Qapzola (Apaziquone) for the Treatment of Non-Muscle Invasive Bladder Cancer (ODAC) - [FDA Decision Report](#)
- [June 28-29, 2016](#): US FDA Advisory Subcommittee Weighs in on Pediatric Oncology Candidates and Discusses Treatment Approaches for Fatal Pediatric Brain Tumor (ODAC) (Pediatric Oncology Subcommittee)
- [April 12, 2016](#): US FDA Advisory Committee Does Not Support Accelerated Approval of Rociletinib by Clovis for EGFR T790M Non-Small Cell Lung Cancer (ODAC) - [FDA Decision Report](#)
- [November 19, 2015](#): US FDA Advisory Committee Discusses Pediatric Written Requests for Two Investigational Cancer Drugs (ODAC)
- [November 18, 2015](#): US FDA Advisory Committee does not Support Telecta Therapeutics' MCNA for Bladder Cancer (CTGTAC/ODAC) - [FDA Decision Report](#)
- [July 9, 2015](#): US FDA Advisory Committee Supports a Favorable Benefit-Risk Assessment of Eli Lilly's Necitumumab for Squamous Non-small Cell Lung Cancer (ODAC) - [FDA Decision Report](#)
- [April 29, 2015](#): US FDA Advisory Committee Supports Amgen's T-Vec to Treat Metastatic Melanoma (CTGTAC/ODAC) - [FDA Decision Report](#)
- [January 7, 2015](#): US FDA Advisory Committee Unanimously Supports Proposed Biosimilar to Amgen's Neupogen by Sandoz, the First to Test a New Abbreviated Pathway for Biosimilars (ODAC) - [FDA Decision Report](#)
- [December 11, 2014](#): US FDA Advisory Committee Discusses Pediatric Written Requests For Three Investigational Cancer Drugs (ODAC)
- [November 6, 2014](#): US FDA Advisory Committee: Does Not Support Novartis' Farydak for Multiple Myeloma, But Does Support Rockwell Medical's Triferic to Maintain Hemoglobin Levels in Patients with Kidney Disease (ODAC) - [FDA Decision Report](#)
- [June 25, 2014](#): US FDA's Advisory Committee Does Not Support AstraZeneca's Lynparza (Olaparib) for Ovarian Cancer (ODAC) - [FDA Decision Report](#)

- [November 5, 2013](#): US FDA's Advisory Committee Discusses Development Plans for PD-1/PD-L1 and CDK4/6 Inhibitors for the Treatment of Pediatric Cancers (ODAC) (Pediatric Oncology Subcommittee)
- [November 4, 2013](#): US FDA's Advisory Committee Discusses Patient Reported Outcomes for Pediatric Cancers (ODAC) (Pediatric Oncology Subcommittee)
- [September 12, 2013](#): US FDA's Advisory Committee Supports Genentech's PERJETA for HER2 Positive Breast Cancer (ODAC)
- [May 3, 2013](#): US FDA's Advisory Committee Almost Unanimously Supports Leukocyte Growth Factors to Treat Myelosuppression from a Radiological/Nuclear Incident (MIDAC/ODAC)
- [May 2, 2013](#) (PM): US FDA's Advisory Committee Votes Unanimously Against Delcath Systems' Melblez Kit for Unresectable Ocular Melanoma Metastatic to the Liver (ODAC)
- [May 2, 2013](#) (AM): US FDA's Advisory Committee Almost Unanimously Does Not Support AVEO's Tivozanib for Advanced Kidney Cancer (ODAC)
- [December 4, 2012](#): US FDA's Advisory Subcommittee Discusses Pediatric Plans for Four Oncology Drugs (ODAC)
- [July 25, 2012](#): US FDA's Advisory Committee Discusses Imaging Tests to Identify Pre-surgical Clear Cell Carcinoma of the Kidney (ODAC)
- [July 24, 2012](#): US FDA's Advisory Committee Discusses Radiographic Review for Progress-Free Survival Endpoints (ODAC)
- [June 20, 2012](#) (PM): US FDA's Advisory Committee Supports Onyx's Kyprolis for Multiple Myeloma (ODAC)
- [June 20, 2012](#) (AM): US FDA's Advisory Committee Does Not Support Sanofi's Semuloparin for Venous Thromboembolism in Cancer Patients (ODAC)
- [March 21, 2012](#): US FDA's Advisory Committee Supports Talon's Marqibo for Leukemia (ALL) (ODAC)
- [March 20, 2012](#) (PM): US FDA's Advisory Committee Does Not Support Merck's Taltorvic for Sarcoma (ODAC)
- [March 20, 2012](#) (AM): US FDA's Advisory Committee Supports Glaxo's Votrient for Soft Tissue Sarcoma (ODAC)
- [February 9, 2012](#): US FDA's Advisory Committee Does Not Support Eisai's Dacogen for Leukemia (AML) (ODAC)
- [February 8, 2012](#): US FDA's Advisory Committee Does Not Support Amgen's XGEVA for Prostate Cancer (ODAC)
- [December 7, 2011](#) (PM): US FDA's Advisory Committee Supports Affymax's Peginesatide for CRF Anemia (ODAC)
- [December 7, 2011](#) (AM): US FDA's Advisory Committee Supports Pfizer's INLYTA for Renal Cell Carcinoma (ODAC)
- [November 2, 2011](#): US FDA's Advisory Committee Discusses Anticoagulant Products in Children (ODAC)
- [November 1, 2011](#): US FDA's Advisory Committee Discusses Pediatric Development Plans (ODAC) (Pediatric Oncology Subcommittee)
- [September 14, 2011](#) (PM): US FDA's Advisory Committee Discusses Products for Non-metastatic Castration Resistant Prostate Cancer (ODAC)
- [September 14, 2011](#) (AM): US FDA's Advisory Committee Supports ApoPharma's FERRIPROX for Transfusional Iron Overload (ODAC)
- [July 14, 2011](#) (PM): US FDA's Advisory Committee Unanimously Supports Accelerated Approval of Seattle Genetics' ADCETRIS for Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ODAC)
- [July 14, 2011](#) (AM): US FDA's Advisory Committee Unanimously Supports Accelerated Approval of Seattle Genetics' ADCETRIS for Relapsed or Refractory Hodgkin's Lymphoma (ODAC)
- [April 12, 2011](#) (PM): US FDA's Advisory Committee Supports Pfizer's SUTENT for Unresectable Pancreatic Neuroendocrine Tumors (ODAC)
- [April 12, 2011](#) (AM): US FDA's Advisory Committee Unanimously Supports Novartis' AFINITOR to Treat Neuroendocrine Tumors (ODAC)
- [February 8, 2011](#) (AM): US FDA's Advisory Committee Hears Updates of Drugs and Biologics Approved via Accelerated Approval, Discusses Trial Requirements (ODAC)
- [December 2, 2010](#): US FDA's Advisory Committee Recommends Postmarket Dosing Studies for iPR Pharmaceuticals' Zictifa for Thyroid Cancer (ODAC)
- [December 1, 2010](#): US FDA's Advisory Committee Does Not Support GlaxoSmithKline's AVODART or Merck's PROSCAR for Prostate Cancer (ODAC)
- [July 20, 2010](#): US FDA's Advisory Committee Does Not Support Genentech's AVASTIN for HER2-Negative Breast Cancer (ODAC)
- March 22, 2010

Vassiliki A. Papadimitrakopoulou, M.D.

Oncologic Drugs Advisory (ODAC) Committee Member

Expertise: Medical Oncology
Term: July 1, 2015 - June 30, 2019
Contact details: Professor of Medicine
The University of Texas MD Anderson Cancer Center
Department of Thoracic Head & Neck Medical Oncology
Division of Cancer Medicine
1515 Holcombe Boulevard
Houston, Texas 77030

[Curriculum Vitae](#)

Voting History:

Meeting [March 7, 2018](#): US FDA Advisory Committee Votes in Support of Amgen's Blincyto for Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia (ODAC) (Oncologic Drugs Advisory Committee (ODAC))

Do the results of MT103-203 demonstrate that for patients with ALL in CR who have MRD > 0.1%, treatment with blinatumomab provides a potential benefit that outweighs the risks from the treatment?

Vote: No

Comment: It was mostly a question of interpretation of the intent of the question here. My interpretation is that we were asked to vote on the question to indicate intent of approving the drug in this indication. Therefore, that tainted my vote. Although I think there is potential benefit, and I think there is plenty of data of a clear need for patients to have some therapy in the setting of MRD, I do not feel that we have the exact definition of the population that benefits.

Meeting [May 24, 2017](#): US FDA Advisory Committee Supports Puma Biotechnology's Neratinib for Breast Cancer and Emmaus Medical's L-Glutamine Solution for Sickle Cell Disease (ODAC)

1. Given the totality of evidence, is the risk-benefit profile of neratinib sufficient to support treatment in the proposed population?

a. Please discuss if there is a subpopulation with a more favorable risk-benefit profile.

Vote: No

Comment: I think the benefit needs to be there. It needs to be clinically meaningful. We didn't see from the overall population that this is clinically meaningful. I think for a subset of patients, they were outlined as the ER positive patients or other subsets, this may be true, but I think voting yes, the way the questions is posed, means that I totally embrace the data for all of the patients, and I don't think the data point in this direction.

Meeting [September 14, 2016](#): US FDA Advisory Committee Unanimously Does Not Support Approval of Spectrum's Qapzola (Apaziquone) for the Treatment of Non-Muscle Invasive Bladder Cancer (ODAC)

Has substantial evidence of a treatment effect for apaziquone over placebo been demonstrated?

Vote: No

Comment: I also voted no. Beyond all the arguments that were already discussed from others, I agree with those. I think the drug has demonstrated activity marker status. I think the agent is safe. I think that it's good that the company's proceeding with additional trials. I would like to add the comment that the urological community likely needs to define the endpoints for these types of trials a little better, based on all the meta analysis and what has been done so far so that actually large randomized status are not preferred with an unclear primary endpoint goal, because to me, it still remains unclear why the 12 percent was chosen.

Meeting [November 18, 2015](#): US FDA Advisory Committee does not Support Telesta Therapeutics' MCNA for Bladder Cancer (CTGTAC/ODAC)

Does MCNA have an overall favorable benefit-risk profile for the treatment of non-muscle invasive bladder cancer at high risk of recurrence or progression in adult patients who failed prior BCG immunotherapy, e.g., in patients who are BCG-refractory or BCG-relapsing?

Vote: No

Comment: I would also agree that there is a need for agents in this particular area and therefore it's very hard to say no. But there are many good scientific reasons to say no. Study design, small population with subsets that benefited that are too small and undefined, lack of anything to really assign the activity to, biomarkers were cited. Other things, clinical pathologic characteristics, nothing that is really clear. I think the drug is safe and I don't think there is harm as long as the patients are monitored and they don't miss their opportunity to get the right therapy. But I do not believe that we should approve drugs on the basis of no harm. I think we should approve them on the basis of benefit. I would also like to say that I was also completely disheartened by the fact that there has been no other approval in this setting and I think trials are feasible even if you think that your population is diverse. That happens in every other disease. Every other disease is a subset. So I think trials need to be brought to the community and the patients can participate then and get to the endpoints.

DISCLAIMER: The information in this document is for informational purposes only. Tarius A/S assumes no liability for any inaccurate or incomplete information, or for any actions taken in reliance thereon. © Tarius A/S. All rights reserved.



CURRICULUM VITAE

Vassiliki A. Papadimitrakopoulou, M.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Jay and Lori Eisenberg Endowed Professorship, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

(b) (6)

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 432
Houston, TX 77030
Phone: (713) 792-6363
Fax: (713) 792-1220
Email: vpapadim@mdanderson.org

EDUCATION

Degree-Granting Education

University of Patras School of Medicine, Patras, Greece, MD, 1988, Medicine

Postgraduate Training

Clinical Internship, Metaxas Cancer Hospital, Piraeus, Greece, 1989-1990

Clinical Residency, Institut Gustave Roussy, Unite La Grange, Savigny Le Temple, France, 1990-1991

Clinical Residency, Internal Medicine, Columbia Presbyterian Medical Center, New York City, 1991-1994

Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1994-1997

Continuing Education, Heart of Leadership Course, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2007-2007

Continuing Education, Faculty Leadership Academy, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2008-2008

Continuing Education, The Path of Women Who Lead, Third WICR Leadership Development Workshop, American Association of Cancer Research, San Diego, CA, 2008-2008

Healthcare Management, Graduate Certificate in Healthcare Management, Rice University, Houston, TX, 2013-2014

CREDENTIALS

Board Certification

Internal Medicine, 1994-2004

Internal Medicine, Medical Oncology, 1997-2018

Licensures

Active

Texas Medical Board, TX, K2553, 1/1997

Inactive

Indiana Medical Board, IN, 01044764, 1/1996

EXPERIENCE/SERVICE

Academic Appointments

Instructor, Department of Thoracic/Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997-1998

Assistant Professor, Department of Thoracic/Head & Neck Medical Oncology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998-2003

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003-2009

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009-present

Administrative Appointments/Responsibilities

Deputy Section Chief, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, 2010-2011

Reviewer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present

Section Chief, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011

Chair, Thoracic Multidisciplinary Planning Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-present

Other Appointments/Responsibilities

Organizer, Thoracic Section Multidisciplinary Protocol Review, Houston, TX, 2011-2013

Organizer, Thoracic Seminar Series, Houston, TX, 2011-2013

Clinical Research Committee Member, Vice Provost Advisory Council, Houston, TX, 2012

Working Group Member: Research Costs for Clinical Protocol Patients Committee, Vice Provost Advisory Council, Houston, TX, 2012

Member, The University of Texas MD Anderson Cancer Center Institutional Review Board, Houston, TX, 2014-present

Study Section Member, The University of Texas MD Anderson Cancer Center Institutional Research Grant Program (IRG), Houston, 2014-present

Endowed Positions

Jay and Lori Eisenberg Endowed Professorship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014-present

Consultantships

Telik Inc., USA, 2001

Sanofi-Aventis, USA, 2003

Novartis, USA, 2005

AstraZeneca, USA, 2006-present

Amgen, Thousand Oaks, CA, 2006
Genentech, USA, 2007-present
Exelixis, USA, 2007
Imclone, USA, 2008
Merck, USA, 2008
Bristol Myers Squibb, USA, 2008
GlaxoSmithKline, USA, 2009
Medimmune, USA, 2011
Clovis Oncology, USA, 2012-present
Eli Lilly, USA, 2013-present
Janssen Pharmaceuticals, USA, 2013-present
Biothera, USA, 2014
Gensignia, USA, 2014

Military or Other Governmental Service

N/A

Institutional Committee Activities

Medical Practice, Subcommittee Member, 2003-2007
PDC/Pharmacology Users Committee, Member, 2005-2006
Clinical Translational Research Center (CTRC) Committee, Member, 2005-2006
Clinical Research Impact Subcommittee of the Clinical Council, Member, 2007-2010
Clinician Investigator Task Force, Member, 2007
Clinical Faculty Review Committee, Member, 2011-2014
Thoracic Cancer Multidisciplinary Program, Chair, 2011-present
Investigational New Drug Committee, Member, 2012-present
Clinical Faculty Review Committee, Vice Chair, 2012
Clinical Faculty Review Committee, Chair, 2013
Residual Funds Committee, Member, 2014-present
Study Section Institutional Research Grant Program Committee (IRG), Member, 2014-present
Institutional Review Board, Member, 2014-present
Molecular Testing Evaluation Committee, Member, 2014

HONORS AND AWARDS

Scholarship Awarded: Stipend of the Greek State, 1982
Research Funds Competition Award, The University of Texas MD Anderson Cancer Center, 1996-1997
Clinical Oncology Merit Award, American Society of Clinical Oncology (ASCO), 1997
Division of Medicine Achievement in Research Award, The University of Texas MD Anderson Cancer Center, 1997
Pharmacia & Upjohn's Award for Outstanding Achievement in Cancer, 1997
Young Investigator Award, American Society of Clinical Oncology (ASCO), 1998
Clinical Research Career Development Award, American Society of Clinical Oncology (ASCO), 2000

Division of Medicine Team Science Award, The University of Texas MD Anderson Cancer Center, 2011

World Wide Who's Who Executives and Professionals in Research, Medicine and Healthcare, 2013

AACR Princess Takamatsu Memorial Lectureship Award Selection Committee, American Association for Cancer Research (AACR), 2014

Doctors of Excellence, Leaders in Healthcare Network, 2014

Excellence in Collaboration and Innovation Award, Bonnie Addario Lung Cancer Foundation, 2014

Invitation to FDA Center for Drug Evaluation and Research's (CDER) ODAC, United States Federal Drug Agency (FDA), 2014, 2015

RESEARCH

Grants and Contracts

Funded

Co-Investigator, 0.6 months, Institutional National Research Science Award, T32CA060374, NIH/NCI, PI - Jeffrey Myers, 7/1/2011-6/30/2016 (\$121,836/year)

Co-Principal Investigator, 0.96 months, Personalizing NSCLC Therapy: Exploiting KRAS activated pathways, R01 CA155196-01A1, NIH/NCI, PI - Roy Herbst, 9/15/2011-7/31/2016 (\$514,442/year)

(b) (4)

(b) (4)

(b) (4)

Principal Investigator, 15%, SWOG - CTI, The Hope Foundation, 1/1/2015-12/31/2015 (\$ (b) (4))

Pending

(b) (4)

Other

N/A

Completed

Principal Investigator, Young Investigator Award: Effects of Biochemoprevention on Cell Cycle Regulator Abnormalities During Head and Neck Tumorigenesis, American Society of Clinical Oncology (ASCO), 1998, \$ (b) (4) 0

Co-Principal Investigator, Biochemoprevention Therapy in Advanced Laryngeal Dysplasia, CA79437-03, NIH/NCI, PI - Waun Ki Hong, 9/10/1998-6/30/2004, \$441,815 (\$88,363/year)

Principal Investigator, Randomized, Double-Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia, CA70907, NIH/NCI, 1/31/2000-1/31/2001, \$107,023

Co-Investigator, Clinical and Epidemiologic Center for Biomarkers of Upper Aerodigestive Tract Lesions, CA86390, NIH/NIBIB, 5/1/2000-2/28/2005, \$123,267 (\$24,653/year)

Principal Investigator, Alterations of Cell Cycle Regulators and their Signaling Partners as Predictors of Response to Chemoprevention and Cancer Risk in Upper Aerodigestive Tract Premalignancy, American Society of Clinical Oncology (ASCO), 7/1/2000-6/30/2003, \$ (b) (6)

Principal Investigator Developmental Research Project, Multitargeted Therapy Aiming at Signal Transduction Pathways in Head and Neck Cancer, Department of Defense (DOD), PI - Hong WK, 3/15/2001-3/15/2009, \$62,500

Principal Investigator, Project 4: SPORE in Head and Neck Cancer - Targeting EGFR for Chemoprevention of Head & Neck Cancers, P50 CA97007-01, NIH/NCI, 8/1/2001-6/30/2006, \$211,391

Co-Investigator, 1.2 months, MDACC SPORE in Head and Neck Cancer, 3P50 CA97007 08, NIH/NCI (PP-3B), PI - Scott Lippman, 7/1/2002-7/31/2013 (\$1,493,507/year)

Principal Investigator, Development Project, Multitargeted therapy aiming at signal transduction pathways in head and neck cancer, P50 CA97007-02, NIH/NCI, 9/30/2002-7/31/2007, \$47,509 (\$47,509/year)

Project 3 Co-Leader, 1.2 months, MD Anderson Cancer Center Head and Neck SPORE (PP-3), 5 P50 CA097007 09, NIH/NCI, PI - Jeffrey Myers, 9/30/2002-7/31/2013 (\$1,493,507/year)

Project 1 Leader, 1.2 months, Molecular-Based Therapy for Oral Cancer Prevention, 5 P01 CA106451 06, NIH/NCI, PI - Scott Lippman, M.D., 8/1/2004-7/31/2012

Co-Investigator, 0.12 months, Early Therapeutic Development with Phase II Emphasis, N01 CM-62202 09, NIH/NCI, PI - David J Stewart, 1/1/2006-9/30/2011 (\$8,317,052/year)

Co-PI, BATTLE Lung Cancer Program, W81XWH-06-1-0303, Department of Defense, PI - Hong, 4/1/2006-4/30/2011

Not Funded

N/A

Protocols

Funded

Principal Investigator, Induction biochemoprevention followed by fenretinide versus placebo maintenance for laryngeal dysplasia, ID98-017, 1998, NCI

Principal Investigator, Randomized, double blind, placebo-controlled, phase IIB trial of ketorolac mouth rinse evaluating the effect of cyclooxygenase inhibition on oropharyngeal leukoplakia: collaborative study of the NCI, NIDCD and the NIDR, ID99-302, 1999

(b) (4)

(b) (4)



Principal Investigator, Phase II ERCC1 and RRM1-based adjuvant therapy trial in patients with stage I non-small cell lung cancer (NSCLC), SWOGS0720, 2011, Southwest Oncology Group (SWOG)

(b) (4)



(b) (4)

Principal Investigator, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer. Study A: MEDI4736; Study B: GDC-0032; Study C: Palbociclib; Study D: AZD4547; Study E: Rilotumumab + Erlotinib, SWOGS1400, 2014

(b) (4)

Unfunded

(b) (4)

(b) (6)
(b) (4)

(b) (6)
(b) (4)

(b) (6)
(b) (4)

Patents and Technology Licenses**Patents**

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Study Section Review Committee for Clinical Translational and Population Based Research Projects under the Institutional Research Grants Program (IRG), MD Anderson Cancer Center, Member, 2014-2017

2015 AACR Princess Takamatsu Memorial Lectureship, American Association for Cancer Research, Member, 2014

PUBLICATIONS**Peer-Reviewed Original Research Articles**

1. Cvitkovic FB, Haie-Meder C, Papadimitrakopoulou V, Armand JP, Cioloca C, Maugis N, Constans JP. Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. *J Neurooncol* 15(1):9-17, 1/1993. PMID: 8384255.
2. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. *Cancer Res* 56(11):2519-21, 6/1996. PMID: 8653689.
3. Sarris AH, Luthra R, Papadimitrakopoulou V, Kimopoulos M, McBride JA, Cabanillas F, Morris S, Deisseroth A, Pugh WC. Amplification of genomic DNA-PCR technique demonstrates the presence of the t(2; 5) rearrangement in anaplastic large cell lymphoma but no other non-Hodgkin's lymphomas; Hodgkin's disease or lymphomatoid papulosis. *Blood* 88:1771-1779, 1996.
4. Papadimitrakopoulou VA, Hong WK, Lee JS, Martin JW, Lee JJ, Batsakis JG, Lippman SM. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. *J Natl Cancer Inst* 89(3):257-8, 2/1997. PMID: 9017007.
5. Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. *Cancer J Sci Am* 3(2):92-9, Mar-Apr, 3/1997. PMID: 9099459.
6. Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelman WN, Lotan R, Hong WK, Mao L. Frequent inactivation of p16INK4a in oral premalignant lesions. *Oncogene* 14(15):1799-803, 4/1997. PMID: 9150385.
7. Sarris AH, Papadimitrakopoulou V, Dimopoulos MA, Smith T, Pugh W, Ha CS, McLaughlin P, Callender D, Cox J, Cabanillas F. Primary parotid lymphoma: the effect of International Prognostic Index on outcome. *Leuk Lymphoma* 26(1-2):49-56, 6/1997. PMID: 9250787.
8. Sarris AH, Papadimitrakopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Ann Oncology* 8:S59-S63, 1997.
9. Sarris AH, Luthra R, Papadimitrakopoulou V, Waasdorp M, Dimopoulos M, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris S, Pugh WC. Rapid amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Ann Oncology* 8 (Suppl 2):S1-S5, 1997.

10. Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L. Presence of multiple in contiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. *Clin Cancer Res* 4(3):539-44, 3/1998. PMID: 9533520.
11. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, Clayman GL, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. *J Clin Oncol* 16(4):1325-30, 4/1998. PMID: 9552033.
12. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. *J Natl Cancer Inst* 90(20):1545-51, 10/1998. PMID: 9790547.
13. Izzo JG, Papadimitrakopoulou VA, Li XQ, Ibarquien H, Lee JS, Ro JY, El-Naggar A, Hong WK, Hittelman WN. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. *Oncogene* 17(18):2313-22, 11/1998. PMID: 9811462.
14. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. *Arch Otolaryngol Head Neck Surg* 125(10):1083-9, 10/1999. PMID: 10522499.
15. Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. *J Natl Cancer Inst* 92(1):69-73, 1/2000. PMID: 10620636.
16. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. *Clin Cancer Res* 6(5):1702-10, 5/2000. PMID: 10815888.
17. Soria JC, Izzo J, Mao L, Hong WK, Papadimitrakopoulou VA. [Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention]. *Bull Cancer* 88(4):351-61, 4/2001. PMID: 11371369.
18. Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. *Cancer* 91(7):1316-23, 4/2001. PMID: 11283932.
19. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK. Combined interferon- α , 13-cis-retinoic acid, and α -tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. *J Clin Oncol* 19(12):3010-7, 6/2001. PMID: 11408495.
20. Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, Hong WK. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. *Clin Cancer Res* 7(10):3127-34, 10/2001. PMID: 11595705.
21. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. *Semin Radiat Oncol* 12(1 Suppl 1):46-9, 1/2002. PMID: 11917284.
22. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. *Clin Cancer Res* 8(2):314-46, 2/2002. PMID: 11839647.

23. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. *Cancer* 95(2):322-30, 7/2002. PMID: 12124833.
24. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. *Cancer* 95(2):340-53, 7/2002. PMID: 12124835.
25. Papadimitrakopoulou VA, Liu DD, Mao L, Shin DM, El-Naggar A, Ibarguen H, Lee JJ, Hong WK, Hittelman WN. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. *Cancer Epidemiol Biomarkers Prev* 11(12):1605-10, 12/2002. PMID: 12496051.
26. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaranga A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. *Clin Cancer Res* 9(1):93-101, 1/2003. PMID: 12538456.
27. Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ, Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. *J Natl Cancer Inst* 95(3):198-205, 2/2003. PMID: 12569141.
28. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. *Oncology (Williston Park)* 17(7 Suppl 7):17-21, 7/2003. PMID: 12886869.
29. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. *Clin Lung Cancer* 5(1):40-5, 7/2003. PMID: 14596703.
30. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Clayman G, Morrison WH, Liu DD, Blumenschein G, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. *Cancer* 98(10):2214-23, 11/2003. PMID: 14601092.
31. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. *J Clin Oncol* 21(24):4546-52, 12/2003. e-Pub 11/2003. PMID: 14597742.
32. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. *Cancer* 100(5):991-8, 3/2004. PMID: 14983495.
33. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. *Clin Cancer Res* 10(5):1565-73, 3/2004. PMID: 15014005.
34. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on

- acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. *Int J Radiat Oncol Biol Phys* 58(5):1369-77, 4/2004. PMID: 15050312.
35. Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvali VK, Munden R, Troung M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. *Cancer Chemother Pharmacol* 54:308-15, 2004. PMID: 15184994.
 36. Mao L, Hong WK, Papadimitrakopoulou V. Focus on head and neck cancer. *Cancer Cell* 5:311-6, 2004.
 37. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. *Clin Cancer Res* 10:2968-76, 2004. PMID: 15131032.
 38. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou V, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. *Clin Cancer Res* 10:658-67, 2004. PMID: 14760089.
 39. Glover K, Perez-Soler R, Papadimitrakopoulou V. Tyrosine Kinase inhibitors in development for non-small cell lung cancer. *Semin Oncology* 31:83-92, 2004.
 40. Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. *Cancer* 103(5):952-9, 3/2005. PMID: 15666322.
 41. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 63(3):717-24, 11/2005. PMID: 16199307.
 42. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. *Cancer* 104(11):2430-6, 12/2005. PMID: 16245318.
 43. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peebles BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. *Cancer* 104 (11)(11):2449-56, 12/2005. PMID: 16258975.
 44. Papadimitrakopoulou V, Agelaki S, Tran HT, Kies M, Gagel R, Zinner R, Kim E, Ayers G, Wright J, Khuri F. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. *Clin Cancer Res* 11:4151-9, 2005. PMID: 15930851.
 45. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, . Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung carcinoma. *Cancer* 104:561-9, 2005.
 46. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou VA, Huang S, Hong WK. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. *Clin Cancer Res* 11 (16):6065-74, 2005.
 47. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. *Clin Cancer Res* 12(10):3109-14, 5/2006. PMID: 16707609.
 48. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. *Clin Cancer Res* 12(14 Pt 2):441S-445S, 7/2006. PMID: 16857825.

49. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY. The Prognostic Role of Loss of Insulin-like Growth Factor-binding Protein-3 Expression in Head and Neck Carcinogenesis. *Cancer Lett* 239(1):136-43, 7/2006. e-Pub 9/2005. PMID: 16181731.
50. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. *J Clin Oncol* 24(25):4163-9, 9/2006. PMID: 16943532.
51. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. *J Thorac Oncol* 1(7):749-51, 9/2006. PMID: 17409953.
52. Kelloff GJ. Lippman SM. Dannenberg AJ. Sigman CC. Pearce HL. Reid BJ. Szabo E. Jordan VC. Spitz MR. Mills GB. Papadimitrakopoulou VA. Lotan R. Aggarwal BB. Bresalier RS. Kim J. Arun B. Lu KH. Thomas ME. Rhodes HE. Brewer MA. Follen M. Shin DM. Parnes HL. Siegfried JM. Evans AA. Blot WJ. Chow WH. Blount PL. Maley CC. Wang KK. Lam S. Lee JJ. Dubinett SM. Engstrom PF. Meyskens FL Jr. O'Shaughnessy J. Hawk ET. Levin B. Nelson WG. Hong WK. AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. *Clin Cancer Res* 12 (12):3661-97, 2006.
53. Lippman SM. Lee JJ. Martin JW. El-Naggar AK. Xu X. Shin DM. Thomas M. Mao L. Fritsche HA Jr. Zhou X. Papadimitrakopoulou V. Khuri FR. Tran H. Clayman GL. Hittelman WN. Hong WK. Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. [Clinical Trial, Phase II. Research Support, N.I.H., Extramural]. *Clin Cancer Res* 12:3109-14, 2006.
54. Gillenwater A. Papadimitrakopoulou V. Richards-Kortum R. Oral premalignancy: new methods of detection and treatment. *Curr Oncol Reports*:146-54, 2006.
55. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Patients with locally Advanced Squamous Cell Cancer of the Head and Neck. *J Clin Oncol* 24:4163-9, 2006.
56. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and MAP Kinase Pathways in Lung Cancer Therapy. *J Thor Oncol* 1 (7):749-51, 2006.
57. Bristol IJ, Ahamad A, Garden AS, Morrison WH, Hanna EY, Papadimitrakopoulou VA, Rosenthal DI, Ang KK. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. *Int J Radiat Oncol Biol Phys* 68(3):719-30, 7/2007. PMID: 17543999.
58. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. *Cancer Biomark* 3(1):1-33, 2007.
59. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. *Invest New Drugs* 26(1):81-7, 2/2008. e-Pub 10/2007. PMID: 17960324.
60. O'Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. *J Clin Oncol* 26(10):1588-95, 4/2008. e-Pub 3/2008. PMID: 18332470.

61. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized Phase II study of celecoxib in oral premalignant lesions. *Clin Cancer Res* 14(7):2095-101, 4/2008. PMID: 18381950.
62. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. *J Clin Oncol* 26:354-60, 2008.
63. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. *Cancer Prev Res (Phila Pa)* 2(1):14-21, 1/2009. PMID: 19139013.
64. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High dose Fenretinide in oral leukoplakia. *Cancer Prev Res (Phila Pa)* 2(1):22-6, 1/2009. PMID: 19139014.
65. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. *J Clin Oncol* 27(4):599-604, 2/2009. e-Pub 12/2008. PMCID: PMC2645856.
66. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, El-Naggar AK, Khuri FR, Chen ZG, Shin DM. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. *Cancer Prev Res (Phila Pa)* 2(9):823-9, 9/2009. e-Pub 9/2009. PMCID: PMC2910364.
67. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. *Clin Cancer Res* 15(19):6284-91, 10/2009. e-Pub 9/2009. PMCID: PMC2756317.
68. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V. Efficacy of Everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. *Ann Oncol* 20(10):1674-91, 10/2009. e-Pub 6/2009. PMID: 19549709.
69. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. *Cancer Prev Res (Phila Pa)* 2(11):931-41, 11/2009. PMID: 19892663.
70. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspay KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results from a Phase II prospective trial. *J Clin Oncol* 28(1):8-14, 1/2010. e-Pub 11/2009. PMCID: PMC2799235.
71. Yildirim G, Morrison WH, Rosenthal DI, Sturgis EM, Papadimitrakopoulou VA, Schwartz DL, Garden AS. Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. *Head Neck* 32(4):473-80, 4/2010. e-Pub 8/2009. PMID: 19691110.
72. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. *Mol Cancer Ther* 9(6):1755-63, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.
73. Benckroun MT, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. *Cancer Prev Res (Phila Pa)* 3(7):800-9, 7/2010. e-Pub 6/2010. PMCID: PMC2900459.
74. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and

- AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. *PLoS One* 5(11):e14124, 2010. e-Pub 11/2010. PMID: PMC2993951.
75. Guo M, Sneige N, Patel S, Feng J, Papadimitrakopoulou V, Sturgis E, Etzel Z, Hong WK, Tsao A. HPV infection and oral cytological changes in patients with oropharyngeal squamous carcinoma and their sexual partners. *Cancer Cytopath* 118(5):349-50, 2010.
 76. Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression profiling predicts the development of oral cancer. *Cancer Prev Res (Phila)* 4(2):218-29, 2/2011. PMID: PMC3074595.
 77. Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Vandetanib restores head and neck squamous cell carcinoma cell's sensitivity to Cisplatin and radiation in vivo and in vitro. *Clin Cancer Res* 17(7):1815-27, 4/2011. e-Pub 2/2011. PMID: PMC3074405.
 78. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. *Cancer* 117(10):2112-9, 5/2011. e-Pub 11/2010. PMID: PMC3117018.
 79. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). *Invest New Drugs* 29(3):499-505, 6/2011. e-Pub 1/2010. PMID: 20094773.
 80. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing therapy for lung cancer. *Cancer Discov* 1(1):44-53, 6/2011. e-Pub 6/2011. PMID: 22586319.
 81. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trial of Imatinib Mesylate and Docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. *J Thorac Oncol* 6(12):2104-11, 12/2011. e-Pub 9/2011. PMID: 21892101.
 82. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. *J Natl Cancer Inst* 104(3):228-39, 2/2012. e-Pub 1/2012. PMID: PMC3274509.
 83. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small cell lung cancer. *J Thorac Oncol* 7(8):1315-26, 8/2012. e-Pub 5/2012. PMID: 22648207.
 84. Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small cell lung cancer: A phase I trial. *J Thorac Oncol* 7(10):1594-601, 10/2012. PMID: 22968184.
 85. Massarelli E, Papadimitrakopoulou VA. Phosphatidylinositol 3-kinase and Mammalian target of rapamycin pathway in non-small-cell lung cancer. *J Thorac Oncol* 7(16 Suppl 5):S379-82, 12/2012. PMID: 23160325.
 86. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DS, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. *J Thorac Oncol* 7(5):825-32, 2012. PMID: PMC3465940.
 87. Papadimitrakopoulou V. Secondary therapeutic strategies for EGF receptor pathway inhibition in non-small cell lung cancer. *Forum Clin Oncol* 3(Spec Issue):45-50, 2012.
 88. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Computed tomography

- RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small cell lung cancer after neoadjuvant chemotherapy. *J Thorac Oncol* 8(2):222-8, 2/2013. e-Pub 1/2013. PMID: PMC3549050.
89. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. *Lung Cancer* 80(3):235-41, 6/2013. e-Pub 2/2013. PMID: 23485129.
 90. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U. First-in-human phase I dose escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. *Clin Cancer Res* 19(13):3671-3680, 7/2013. e-Pub 6/2013. PMID: 23757357.
 91. Tsao AS, Papadimitrakopoulou V. The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non-Small-Cell Lung Cancer: Focus on Clinical Trial Results. *Clin Lung Cancer* 14(4):311-21, 7/2013. e-Pub 4/2013. PMID: 23582282.
 92. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. *Int J Radiat Oncol Biol Phys* 87(1):139-47, 9/2013. PMID: 23920393.
 93. Hellmann MD, Chaff JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, Heymach JV, Blumenschein G, Cox JD, Hofstetter W, Fang B, Fossella F, Glisson B, Hong WK, Gold K, Johnson F, Kies MS, Liao Z, Lin S. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. *Lancet Oncology* 15(1):e42-50, 1/2014.
 94. Besse B, Heist RS, Papadimitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenäinen I, Petrovic K, Johnson BE. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. *Ann Oncol* 25(2):505-11, 2/2014. e-Pub 12/2013. PMID: 24368401.
 95. Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naïve, advanced non-small cell lung cancer. *Invest New Drugs* 32(1):123-34, 2/2014. e-Pub 4/2013. PMID: 23579358.
 96. Besse B, Leigh N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, Soria JC, Gogov S, Miller N, Jehl V, Johnson BE. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. *Ann Oncol* 25(2):409-15, 2/2014. e-Pub 12/2013. PMID: 24368400.
 97. Hutcheson KA, Lewin JS, Holsinger FC, Steinhaus G, Lisec A, Barringer DA, Lin HY, Villalobos S, Garden AS, Papadimitrakopoulou V, Kies MS. Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. *Head Neck* 36(4):474-80, 4/2014. e-Pub 6/2013. PMID: 23780650.
 98. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. *Head Neck*. e-Pub 10/2014. PMID: 25352401.
 99. Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. *Head Neck* 36(11):1547-54, 11/2014. e-Pub 3/2014. PMID: PMC4010580.
 100. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA,

- Yan L, de Bono JS. Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK. *Clin Cancer Res.* e-Pub 12/2014. PMID: 25516890.
101. Dimou A, Papadimitrakopoulou V. Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. *J Pers Med* 4(3):386-401, 2014. e-Pub 6/2014. PMID: PMC4263964.
102. Massarelli E, Papadimitrakopoulou V. Ceritinib for the Treatment of Late-Stage (Metastatic) Non-Small Cell Lung Cancer. *Clin Cancer Res.* e-Pub 1/2015. PMID: 25564153.
103. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman M, Hirsch F, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. *Clin Pharmacol Ther.* e-Pub 2/2015. PMID: 25676724.
104. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. *Clin Cancer Res.* e-Pub 2/2015. PMID: 25680375.
105. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol.* e-Pub 5/2015. PMID: 26025965.



Invited Articles

1. Papadimitrakopoulou VA, Shin DM, Hong WK. Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. *Cancer Metastasis Rev* 15(1):53-76, 3/1996. PMID: 8842479.
2. Papadimitrakopoulou VA, Hong WK. Biology of oral premalignant lesions: concepts and implications for chemoprevention. *Eur J Cancer Prev (Supp 2)*:8-93, 12/1996. PMID: 9061300.
3. Papadimitrakopoulou VA, Hong WK. Retinoids in head and neck chemoprevention. *Proc Soc Exp Biol Med* 216(2):283-90, 11/1997. PMID: 9349698.
4. Papadimitrakopoulou VA, Hong WK. Retinoids in head and neck chemoprevention. *Proc Soc Exp Biol Med* 216(2):283-90, 1997. PMID: 9349698.
5. Geyer C, Papadimitrakopoulou V, Hong WK. Chemoprevention in head and neck cancer: basic science and clinical application. *Semin Radiat Oncol* 8(4):292-301, 10/1998. PMID: 9873107.
6. Papadimitrakopoulou V, Ayoub JP, Hong WK. New development in the chemoprevention of lung cancer. *Primary Care and Cancer* 18:51-56, 1998.

7. Papadimitrakopoulou VA, Hong WK. Combined-modality therapy in paranasal sinus cancer. *Cancer J Sci Am* 5(4):208-10, Jul-Aug, 7/1999. PMID: 10439164.
8. Papadimitrakopoulou VA. Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. *Curr Opin Oncol* 12(3):240-5, 5/2000. PMID: 10841196.
9. Papadimitrakopoulou VA, Hong WK. Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. *Int J Cancer* 88(6):852-5, 12/2000. PMID: 11093804.
10. Papadimitrakopoulou VA. Chemoprevention of head and neck cancer: an update. *Curr Opin Oncol* 14(3):318-22, 5/2002. PMID: 11981278.
11. Glover KY, Papadimitrakopoulou VA. Chemoprevention of head and neck cancer. *Curr Oncol Rep* 5(2):152-7, 2003. PMID: 12583833.
12. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. *Cancer Cell* 5(4):311-6, 4/2004. PMID: 15093538.
13. Tsao AS, Papadimitrakopoulou VA. The future of NSCLC molecular profiles guiding treatment decisions. Comment on "ALK-Targeted Therapy for Lung Cancer. Ready for Prime Time. *Oncology (Williston Park)* 25(7):607, 614, 6/2011. PMID: 21888260.
14. Tsao AS, Papadimitrakopoulou V. Mitotic Inhibitors. *J Thorac Oncol* 6(11 Suppl 4):S1789-90, 11/2011. PMID: 22005531.
15. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in Lung Cancer. *Transl Lung Cancer Res* 3(1):53-63, 2/2014.

Editorials

1. William WN, Papadimitrakopoulou VA. Optimizing Biomarkers and Endpoints In Oral Cancer Chemoprevention Trials. *Cancer Prev Res (Phila)* 6(5):375-8, 5/2013. PMID: PMC3683314.

Other Articles

N/A

Abstracts

1. Papadimitrakopoulou V, Shin DM, Clayman G, El Naggar A, Martinez L, Gillenwater A, Goepfert H, Hong WK. Biochemoprevention or advanced premalignant lesions in the upper aerodigestive tract. Seventh International Congress on anti-cancer treatments. Paris, France, P386, 2/1997.
2. Papadimitrakopoulou V, Shin DM, Clayman G, El-Naggar A, Shin HJ, Lippman SM, Martinez L, Gillenwater A, Callender D, Gopfert H, Hong WK. Efficacy of biochemoprevention in reversal of advanced premalignant lesions (PLs) of the upper aerodigestive tract (UADT). *Proc Am Soc Clin Oncol* 16:1366, 1997.
3. Papadimitrakopoulou V, Izzo JG, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelman WN, Lotan R, Hong WK, Mao L. Frequent inactivation of p16INK4a in oral premalignant lesions. *Proc Am Assoc Cancer Res* 38:1646, 1997.
4. Shin DM, Mao L, Papadimitrakopoulou V, El-Naggar A, Clayman G, Shin HJ, Lee JS, Lippman SM, Gillenwater A, Hittelman WN, Hong WK. Modulation of biomarkers with chemopreventive therapy in advanced premalignant lesions in the upper aerodigestive tract. *Proc Am Soc Clin Oncol* 16:1557, 1997.
5. Sarris AH, Papadimitrakopoulou V, Dimopoulos MA, Braunschweig I, Smith T, Pugh WC, Rodriguez MA, Ha C, Callender D, Cox J, McLaughlin P, Cabanillas F. Primary parotid lymphoma: the effect of International Prognostic Index on outcome. *Proc Am Soc Clin Oncol* 16:65, 1997.
6. Geyer C, Papadimitrakopoulou V, Lee JS, Lippman S, Xu XC, Lee J, Hong WK, Lotan R. A lack of association among the basal level of retinoic acid receptor b (RARb) mRNA in oral premalignant lesions (OPLS), its upregulation by 13-cis-retinoic acid (13cra) and cancer development during a long-term follow-up. *Proc Am Soc Clin Oncol* 17:1506, 1998.
7. Izzo J, Papadimitrakopoulou V, Mao L, Ro JY, Hong WK, Hittelman WN. Cyclin D1 (CCND1) overexpression and 9p21 loss promote CCND1 amplification and p53 alterations during head and neck (HNSC) tumorigenesis. *Proc Am Assoc Cancer Res* 39:2377, 1998.
8. Mao L, Fan YH, Shin DM, Papadimitrakopoulou V, El-Naggar AK, Izzo GJ, Lee JS, Clayman G, Shin HJ, Hittelman WN, Lippman SM, Hong WK. Loss of heterozygosity (LOH) at 9p21 is

- frequent in head and neck preneoplastic lesions (HNPLs) and independent of clinical parameters. *Proc Am Assoc Cancer Res* 39:2453, 1998.
9. Papadimitrakopoulou V, Khuri FR, Lippman SM, Shin DM, Ginsberg L, Glisson BS, Martinez L, Loewen G, Truglia J, Hong WK. Phase I/II evaluation of targretin (LGD 1069), a novel, RXR-specific retinoid, in patients with recurrent squamous cell carcinoma of the head and neck. *Proc Am Soc Clin Oncol* 17:1512, 1998.
 10. Papadimitrakopoulou V, Oh Y, El-Naggar A, Izzo J, Clayman G, Hong WK, Mao L. Presence of multiple inconspicuous deleted regions at the long arm of chromosome 18 in head and neck cancer. *Proc Am Assoc Cancer Res* 39:2330, 1998.
 11. Papadimitrakopoulou V, Shin DM, Clayman G, El-Naggar A, Myers J, Lewin J, Lawhorn K, Gillenwater A, Diaz E, Goepfert H, Hong WK. Biochemoprevention for advanced premalignant lesions (APL) of the upper aerodigestive tract (UADT): a promising biologic approach for laryngeal dysplasia. *Proc Am Soc Clin Oncol* 18:1525, 1999.
 12. Papadimitrakopoulou V, Izzo J, Keck JM, Mao L, El-Naggar AK, Shin DM, Hittelman WN, Hong WK. Biochemoprevention for dysplastic aerodigestive tract lesions: effects of cyclin D1 and p16 abnormalities. *Proc AACR-NCI-EORTC Int Conf* 5:3866s:684, 1999.
 13. Papadimitrakopoulou V, Izzo J, Keck J, Mao L, El-Naggar A, Shin DM, Hittelman WN, Hong WK. Biochemoprevention-effects on cell cycle regulation. *Proc Am Assoc Cancer Res* 40:2832, 1999.
 14. Izzo J, Papadimitrakopoulou V, El-Naggar A, Lee JJ, Hong WK, Hittelman WN. Detection of clonal genetic events preceding tetraploidization and cyclin D1 (CCND1) gene amplification during head and neck (HNSCC) tumorigenesis. *Proc Am Assoc Cancer Res* 40:945, 1999.
 15. Shin DM, Mao L, Papadimitrakopoulou V, Clayman G, El-Naggar A, Shin HJC, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Modulation of the p53 gene and protein and pathologic responses to biochemoprevention in patients with advanced premalignant lesions. *Proc Am Assoc Cancer Res* 40:4124, 1999.
 16. Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson BS, Shin DM, Pisters KM, Papadimitrakopoulou V, Kurie JM, Perez-Soler R, Liu D, Munden R, Hong WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. *Proc Am Soc Clin Oncol* 18:1782, 1999.
 17. Shin DM, Khuri FR, Glisson BS, Reyes J, Ginsberg L, Papadimitrakopoulou V, Herbst R, Lee JJ, Goepfert H, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin (TIC) in patients (PTS) with recurrent squamous cell carcinoma of the head and neck (SCCHN). *Proc Am Soc Clin Oncol* 18:1521, 1999.
 18. Izzo J, Koster MI, Papadimitrakopoulou V, El-Naggar AK, Hong WK, Hittelman WN. Fragile site (FRA) upregulation defines a distinct pathway of head and neck (HN) tumorigenesis. *Proc Am Assoc Cancer Res* 41:69:443, 2000.
 19. Hittelman WN, Papadimitrakopoulou V, El-Naggar AK, Clayman G, Myers J, Lee JS, Corrales C, Lee JJ, Hong WK, Shin DM. High genetic instability is associated with poor therapeutic outcome following biochemopreventive treatment of advanced premalignant lesions (APL) of the larynx and oral cavity. *Proc Am Assoc Cancer Res* 41:223:1421, 2000.
 20. Papadimitrakopoulou V, Mao L, Izzo JG, Keck J, Shin DM, El-Naggar AK, Clayman G, Hittelman WN, Hong WK. Multiple mechanisms of p16 inactivation in advanced premalignant lesions (APL) of the upper aerodigestive tract (UADT). *Proc Am Assoc Cancer Res* 41:223:1422, 2000.
 21. Kim KB, Khuri FR, Shin DM, Papadimitrakopoulou V, Terry K, Perez-Soler R, Hong WK. Phase I trial of weekly topotecan and gemcitabine in patients (pts) with solid tumors. *Proc Am Soc Clin Oncol* 19:220:858, 2000.
 22. Papadimitrakopoulou V, Glisson BS, Khuri FR, Lippman SM, Ginsberg LE, Diaz EM, Jr., Lee J, Garden AS, Ang K, Geopfert H, Hong WK, Shin DM. Phase II study of induction chemotherapy with paclitaxel (T), ifosfamide (I) and carboplatin (C) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (SCCHN). *Proc Am Soc Clin Oncol* 19:420:1659, 2000.
 23. Hittelman WN, Shin DM, Mao L, Papadimitrakopoulou V, Lee J, El-Naggar AK, Lippman SM, Clayman GL, Myers JN, Shin HJ, Lee JS, Hong WK. Pretreatment biomarkers predict

- response of advanced head and neck premalignant lesions to biochemoprevention. *Proc Am Soc Clin Oncol* 19:414:1636, 2000.
24. Izzo J, Babenko I, den Hollander P, Hong WK, Hittelman WN, Papadimitrakopoulou V. . Cyclin D1 genotypes: Impact on expression and risk of cancer development in the upper aerodigestive tract. *Proc Am Assoc Cancer Res* 42:342:1843, 2001.
 25. Cohen EEW, Papadimitrakopoulou V, Silverman S, Jesse M, Thomas M, Kirn D, Hong WK, Vokes EE, Rudin CM. . A Phase II Trial of an Attenuated Adenovirus, Onyx-015, as Mouthwash Therapy for Premalignant Oral Dysplasia. *Proc Am Soc Clin Oncol* 20:229a:915, 2001.
 26. Tran HT, Blumenschein GR Jr, Madden T, Shin DM, Khuri F, Fossella F, Papadimitrakopoulou V, Lee JS, Haas A, Dordal M, Hong WK, Herbst RS. . Phase I Study of the Angiogenesis Inhibitor TNP-470 in Combination with Paclitaxel (P) and Carboplatin (CPT) in Patients with Solid Tumors. *Proc Am Soc Clin Oncol* 20:99a:394, 2001.
 27. Papadimitrakopoulou V. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. *AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics*:276, 2001.
 28. Papadimitrakopoulou V, Lozada J, Henderson T, Brito R, McGarry W, Glisson B, Herbst RS, Zinner R, Lee JS, Valero V, Hong WK, Khuri FR. A phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as front-line and second-line therapy. *Proc Am Soc Clin Oncol* 20:259b:2789, 2001.
 29. Papadimitrakopoulou V, den Hollander P, El-Naggar A, Hittelman WN, Hong WK, Izzo J. Frequent and early alterations in b-catenin expression during head and neck tumorigenesis. *Proc Am Assoc Cancer Res* 42:576:3090, 2001.
 30. Swisher S, Roth J, Komaki R, Hicks M, Ro J, Hong WK, Ahrar K, Correa A, Dolormente M, Dreiling L, Fang B, Fossella F, Francisco R, Glisson B, Herbst R, Huaranga A, Gu J, Kelly J, Kemp B, Khuri F, Kurie J, Lee J, Lee JS, Liao Z, Merritt J, Morice R, Morello F, Mosheim M, Munden R, Papadimitrakopoulou V, Pisters K, Putnam J, Sarabia A, Shelton T, Stevens C, Shin D, Smythe W, Vaporciyan A, Walsh G, Yin M, Yver A. Induction of Pro-Apoptotic Mediators and Tumor Regression Following Intratumoral Delivery of Adenoviral p53 (RPR/INGN 201) and Radiation Therapy in Patients with Non-Small Cell Lung Cancer (NSCLC). *Proc Am Soc Clin Oncol* 20:257a:1024, 2001.
 31. Glisson BS, Garden A, Shin D, Morrison W, Papadimitrakopoulou V, Clayman G, Khuri F, Schechter N, Eicher S, Goepfert H, Ang KK, Hong WK. Neoadjuvant Cisplatin/5-FU (PF) Followed by Boost Chemoradiation for Advanced T Stage Nasopharyngeal Cancer. Neoadjuvant Cisplatin/5-FU (PF) Followed by Boost Chemoradiation for Advanced T Stage Nasopharyngeal Cancer. *Proc Am Soc Clin Oncol* 20:232a:926, 2001.
 32. Komaki R, Lee JS, Kaplan B, Allen P, Kelly J, Liao Z, Stevens C, Fossella F, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Cox JD. Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol* 20:325a:1298, 2001.
 33. Mandal M, Adam L, Wang RA, El-Naggar A, Papadimitrakopoulou V, Lotan R, Hong WK, Kumar R. . Inhibition of p21-activated kinase 1, directional cell motility and invasion of growth-factor-activated human cancer cells by the selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839. *Proc Am Assoc Cancer Res* 43:157:786, 2002.
 34. Papadimitrakopoulou V, Figlin R, Garland L, Von Hoff D, Kris M, Purdom M. A Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with non-small cell lung cancer who failed prior platinum-based regimens). 14th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt, Germany 38:S36:106A, 2002.
 35. Papadimitrakopoulou V, Henderson E, Breimer L, Dhingra K, Zhi J, Ritland SR, Lee JS. A phase I clinical and pharmacokinetic study of oral Ro31-7453, a novel cell cycle inhibitor, administered in combination with paclitaxel. *Proc Am Soc Clin Oncol* 21:6b:1830, 2002.
 36. Murren JR, Papadimitrakopoulou V, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese JL. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166; a novel tyrosine kinase inhibitor, in patients with advanced cancers. *Proc Am Soc Clin Oncol* 21:95a:377, 2002.


37. Papadimitrakopoulou V, Kies M, Glisson B, DeMario M, Henderson T, Ritland S. A Phase I study of R0 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results. . 14th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt Germany 38:S49:151, 2002.
38. Cohen EW, Papadimitrakopoulou V, Silverman SJ, Recant W, El-Naggar A, Hong WK, Freeman S, Vokes EE, Rudin CM7. A Phase II trial of an attenuated adenovirus, ONXY-015, as mouthwash therapy for premalignant dysplastic oral lesions. 14th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt Germany 38:S84:272, 2002.
39. Papadimitrakopoulou V, Myers J, Atwell A, Lewin J, El-Naggar A, Hong WK. Biochemoprevention for laryngeal dysplasia: Initial accrual and compliance report. *Frontiers in Cancer Prevention Research* 99:A320, 2002.
40. Izzo J, Papadimitrakopoulou V, Den Hollander PLC, Liu D, El-Naggar A, Hong WK Hittelman WN. Cyclin D1 A870G polymorphism enhances genomic instability during head and neck tumorigenesis. *Proc Am Assoc Cancer Res* 43:293:1456, 2002.
41. Massarelli E, Brown E, Tran N, Papadimitrakopoulou V. E-cadherin expression is lost early in head and neck tumorigenesis. *Frontiers in Cancer Research* 123:B315, 2002.
42. Johnson FM, Kurie JM, Pisters KM, Fossella FV, Peeples BO, Papadimitrakopoulou V, Blumenschein GR, Kies MS, Komaki R, Glisson BS. Phase I trial of weekly etoposide (E), cisplatin (P), and irinotecan (I) with G-CSF in patients with small-cell lung cancer (SCLC). *Proc Am Soc Clin Oncol* 21:213a:1244, 2002.
43. Henner WD, Figlin RA, Garland LL, Von Hoff D, Gitlitz BJ, Purdom M, Martin E, Brown GL, Dombroski J, Maack C, Macpherson J, Woodrow P, Kyle P, Nichois A, Papadimitrakopoulou V. Phase II study of TLK286 (GST PI-1 activated glutathione analog) in advanced non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol* 21:313a:1249, 2002.
44. Komaki R, Lee JS, Milas L, Kaplan B, Allen P, Liao Z, Stevens CW, Fossella FV, Zinner RG, Papadimitrakopoulou V, Khuri F, Herbst RD, Kies MS, Blumenschein GR, Glisson B, Hong WK, Morice R, Cox JD. Phase III Trial of Amifostine With Chmoradiation for Inoperable Non-Small Cell Lung Cancer (NSCLC): Does Amifostine Protect Cancer Cells? *Am Soc Therapeut Rad Oncol*:8909, 2002.
45. Khuri F, Gillenwater A, Diaz E, Lewin J, Shin D, Glisson BS, Herbst RS, Steinhaus G, Altamirano E, Taylor S, Clayman G, Myers J, Papadimitrakopoulou V, Lippman S. Pilot trial of paclitaxel, ifosfamide and cisplatin (TIP) as induction or exclusive therapy for intermediate to advanced laryngeal cancer. *Proc Am Soc Clin Oncol* 21:277a:906, 2002.
46. Papadimitrakopoulou V, Tran N, Den-Hollander P, Hong WK, Izzo J. Role of E-cadherin complex abnormalities in carcinogenic progression of head and neck premalignant lesions. *Proc Am Assoc Cancer Res* 43:311:1544, 2002.
47. Jones SF, Burris HA, Kies M, Willcutt N, Degen P, Bai S, Mauro D, Decillis A, Youssoufian H, Papadimitrakopoulou V. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. *ASCO, 39th Annual Meeting, Chicago, IL* 199:2011, 2003.
48. Johnson FM, Garden A, Kies M, Clayman G, Brumfield B, Khuri F, Morrison W, Papadimitrakopoulou V, Diaz E, Glisson B. A phase II study of docetaxel (D) and carboplatin (C) as neoadjuvant therapy for patients with low T, high N stage nasopharyngeal carcinoma (NPC). *ASCO, 39th Annual Meeting, Chicago, IL* 22:510:2053, 2003.
49. Massarelli E, Liu D, El-Naggar A, Hong WK, Papadimitrakopoulou V. Akt activation correlates with adverse outcome in tongue cancer. *American Society of Clinical Oncology (ASCO) 39th Annual Meeting, Chicago, IL*, 2003.
50. Massarelli E, Liu D, El-Naggar A, Hong WK, Papadimitrakopoulou V. Akt activation correlates with adverse outcome in tongue cancer. *Cancer* 104(11):2430-6, 2003. PMID: 16245318.
51. Zinner R, Obasaju CK, Fossella FV, Papadimitrakopoulou V, Pisters KMW, O'Day MR, Peeples BO, Hatfield AK, Hong AK, Herbst RS. Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): A phase II trial. *ASCO, 39th Annual Meeting, Chicago, IL* 22:642:2580, 2003.

52. Papadimitrakopoulou V, Brown E, Liu D, El-Naggar A, Hong WK. IGFBP Loss predicts for adverse outcome in head and neck squamous cell carcinoma. 94th Annual Meeting, American Association for Cancer Research, Washington, D.C.:2019, 2003.
53. Glover KY, Ginsberg L, Garden A, Glisson B, Diaz E, Kies M, Clayman G, Goepfert H, Hong W, Papadimitrakopoulou V. Intraarterial cisplatin, intravenous paclitaxel, and ifosfamide as an organ preservation approach in paranasal sinus squamous cell cancer. ASCO, 39th Annual Meeting, Chicago, IL 22:505:2034, 2003.
54. Papadimitrakopoulou V, Figlin R, Garland L, Blumenschein G, Fossella F, Von Hoff DD, King L, Brown GL, Mascavage J, Henner WD. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens. ASCO, 39th Annual Meeting, Chicago, IL 22:655:2636, 2003.
55. Glisson B, Garden A, Kies M, Schechter N, Myers J, Zentgraf R, Papadimitrakopoulou V, Lewin J, Clayman G, Ang K-K. Phase II study of docetaxel (D), cisplatin (P), and concomitant boost radiation (CB-RT) for patients with locally advanced squamous cancer of the head and neck (SCHN). ASCO, 39th Annual Meeting, Chicago, IL 22:500:2011, 2003.
56. Kurup A, Hanna N, Falk S, O'Brien M, Von Pawel J, Gatzemeier U, Papadimitrakopoulou V, Rosso R, Demario M, Dhingra K. Phase II study of Ro 31-7453 in patients with recurrent stage III with pleural effusion or stage IV non small cell lung cancer (NSCLC). ASCO, 39th Annual Meeting, Chicago, IL 22:678:2725, 2003.
57. Tsao AS, Kim ES, Nazario A, Fossella FV, Glisson BS, Zinner R, Henderson T, Liu D, Papadimitrakopoulou V, Khuri FR. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as frontline and second-line therapy. ASCO, 39th Annual Meeting, Chicago, IL 22:691:2779, 2003.
58. Massarelli E, Brown E, Tran N, Papadimitrakopoulou V. Predictive role of p27 loss of protein expression alone and in association with loss of E-cadherin protein expression in preneoplastic lesions of head and neck. Proc Am Ass Can Res (AACR) 1896, 2003.
59. Koshy S, Herbst RS, Obasaju CK, Fossella F, Papadimitrakopoulou V, Pisters KMW, Blumenschein G, Peeples BO, Hong WK, Zinner RG. A phase II trial of pemetrexed (P) plus carboplatin (C) in patients with (pts) with advanced non-small cell lung cancer (NSCLC). ASCO 40th Annual Meeting, New Orleans, Louisiana.:7074, 2004.
60. Papadimitrakopoulou VA, Lnu S, Brown E, Angelaki S. Combined effects of inhibition of mTOR and EGFR signaling on apoptosis and kinase pathways in non-small cell lung cancer cell lines. AACR 95th Annual Meeting, Orlando, Florida:4833, 2004.
61. Izzo JG, Hittelman WN, Liu DD, Lee JJ, Wu X, Hong WK, Papadimitrakopoulou VA. Cyclin D1 polymorphism, biochemoprevention and risk of upper aero-digestive tract cancer development. ASCO 40th Annual Meeting, New Orleans, Louisiana:1006, 2004.
62. Letrent S, Callegari F, Wong T, Burris H, Cohen R, Lorusso P, Papadimitrakopoulou V, Shapiro G, Griffin T, Decillis A. Evaluation of a novel RNA biomarker of CDK2 inhibition in phase 1 clinical trials with BMS-387032. ASCO 40th Annual Meeting, New Orleans, Louisiana:2031, 2004.
63. Komaki R, Allen P, Glisson B, Lu C, Kaplan B, Fossella F, Liao Z, Jeter M, Stevens C, Chang J, Blumenschein G, Hong WK, Herbst R, Papadimitrakopoulou V, Kim E, Cox JD. Hyperfractionated and accelerated thoracic radiation therapy (HFxA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy. ASTRO, 2004.
64. Angelaki SI, El-Naggar AK, Brown EN, Lnu S, Ayers GD, Lee JJ, Papadimitrakopoulou VA. Molecular characterization of the P13/Akt pathway in head and neck squamous cell cancer (HNSCC). ASCO 40th Annual Meeting, New Orleans, Louisiana:9643, 2004.
65. Tran HT, Zinner R, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum B, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer (NSCLC). ASCO 40th Annual Meeting, New Orleans, Louisiana:2050, 2004.
66. Papadimitrakopoulou V, Boasberg P, Figlin R, Zinner R, Blumenschein G, King L, Truong M, Patel K, Brown GL, Hanna N. Phase 1-2a dose ranging study of TLK286 (a novel glutathione

- analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC). ASCO 40th Annual Meeting, New Orleans, Louisiana,:7140, 2004.
67. Blumenschein G, Lu C, Kies M, Glisson B, Papadimitrakopoulou V, Zinner R, Kim E, Gillenwater A, Chiao J, Hong W. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer (SCCHN). ASCO 40th Annual Meeting, New Orleans, Louisiana:5578, 2004.
 68. Angelaki S, Lnu S, Brown E, Ayers G, Papadimitrakopoulou VA. Experimental and Molecular Therapeutics 37: Prognostic and Predictive Markers: Synergistic interactions of the Hsp90 inhibitor 17AAG and the PI3K inhibitor LY294002 in non-small cell lung cancer (NSCLC) cell lines involve disruption of Akt and c-raf signalling. AACR Meeting Abstracts, 2005.
 69. Papadimitrakopoulou V, Edelman M, Zinner R, Blumenschein G Jr, Jones S, Willcutt N, Keck J, Brown G, Burris H. Phase 1-2 dose-ranging trial of TLK286 (TELCYTA) and cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC). 11th World Conference on Lung Cancer, Barcelona, Spain:7126, 2005.
 70. Burris HA, Edelman MJ, Stewart D, Fossella F, Jones S, Willcutt N, Keck JG, Brown GL, Papadimitrakopoulou V. Phase II dose-ranging study of TLK286 a novel glutathione analog prodrug, in combination with cisplatin as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC). 2005 ASCO Annual Meeting, Orlando, Florida:7126, 2005.
 71. Choe MS, Tighiouart M, Rogatko A, Muller S, Shin HJ, Francisco M, Papadimitrakopoulou VA, Khuri FR, Hong WK, Chen Z, Shin DM. Role of cyclooxygenase-2 (COX-2) expression in tumor progression and survival in the squamous cell carcinoma of the head and neck (HNSCC). 2005 ASCO Annual Meeting, Orlando, Florida:5508, 2005.
 72. Boyle JO, Ondrey FG, Nathan CO, Brenner DE, Yueh B, Peterson DE, Dannenberg AJ, Burney K, Lippman SM, Papadimitrakopoulou VA. Clinical Prevention Trials: Organ Site Specific Investigations: Head and Neck Cancers: A double-blind, placebo controlled, randomized phase II study of celecoxib in patients with oral premalignant lesions (OPL). AACR Meeting Abstracts, 2006.
 73. Papadimitrakopoulou VA, Fiorentino S, Naeemuddin M. Experimental and Molecular Therapeutics 38: Novel Antitumor Agents 3: Potent activity of the heat shock protein 90 (Hsp90) inhibitor, 17AAG in head and neck squamous cell carcinoma (HNSCC) lines. AACR Meeting Abstracts, 2006.
 74. Papadimitrakopoulou VA. Invited Abstract: Head and Neck Cancer: Risk Assessment and Prevention: Overview of chemoprevention strategies for head and neck cancer. AACR Meeting Abstracts, 2006.
 75. Papadimitrakopoulou V. Overview of Chemoprevention in Head and Neck Squamous Cell Cancer: Molecular Screening and Risk Prediction. Workshop on Imaging Science Development for Cancer Prevention and Preemption, 2006.
 76. Morrow PH, Glisson BH, Ginsberg LE, Lippman SM, Kies MS, Blumenschein GR, Ayuste RC, Feng L, Papadimitrakopoulou V, Kim ES. A phase I dose escalation study of pemetrexed in patient in advanced head and neck squamous cell cancer (HNSCC). Proc of the 2007 ASCO Annual Meeting, Chicago 25(18S):6055, 2007.
 77. Papadimitrakopoulou V, Soria JC, Douillard JI, Giaccone G, Wolf J, Crino L, Cappuzzo F, Sharma S, Gross S, Shepherd FA. A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). Proc. 12th World Congress in Lung Cancer. Seoul, Korea, September 2-6, 2007 (abstract C1-02) S2(8):S359, 2007.
 78. Papadimitrakopoulou V, Soria JC, Douillard JY, Giaccone G, Wolf J, Crino L, Capuzzo F, Sharma S, Gross SH, Shepherd FA. A phase II study of RAD001 ® (everolimus) monotherapy in patients (pts) with advanced non-small cancer (NSCLC) failing prior platinum-based chemotherapy © or prior C and EGFR inhibitors (EGFR-I). Proc of the 2007 ASCO Annual Meeting 25(18S):7589, 2007.
 79. Kim ES, Kies MS, Glisson BS, Tsao A, Ginsberg LE, Holsinger FC, Burke BJ, Truong M, Papadimitrakopoulou V, Lippman SM. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. Proc of the 2007 ASCO Annual Meeting, Chicago 25(18S):6013, 2007.

80. Papadimitrakopoulou V, Blumenschein GR, Leighi NB, Bennouna J, Soria JC, Burris III HA, Dimitrijevic S, Kunz T, Di Scala L, Johnson BE. A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results. Proc. of the 2008 ASCO annual meeting, Chicago, IL 26 (15S)(8051):436s, 2008.
81. Papadimitrakopoulou, V. Molecular targeting, high risk, and other aspects of chemoprevention in the head and neck. Proc. of the 2008 AACR Annual Meeting, San Diego, CA April 12-16, 2008, 2008.
82. Byers LA, Kies MS, William WN, Hu J, Lee JJ, El_Naggar A, Papadimitrakopoulou V, Myers JN, Lippman SM, Heymach JV. Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following chemotherapy. Proc. of the 2008 ASCO Meeting, Chicago, IL 26 (15S)(6005):317s, 2008.
83. Papadimitrakopoulou V. Everolimus (RAD001C) in combination with Carboplatin (C) and Paclitaxel (P) as first line treatment for patients (pts) with advanced NSCLC: A phase I trial. Proc. of the 13th World Conference on Lung Cancer, San Francisco, CA (#Abs 7141), 2009.
84. Papadimitrakopoulou V, Frank SJ, Blumenschein GR Jr, Chen C, Kane M, Cohen EE, Langmuir P, Krebs AD, Lippman SM, Raben D. Phase I evaluation of vandetanib with radiation therapy (RT) +/- cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). Proc. of ASCO Annual meeting, Orlando, FL (#6016), 2009.
85. Saintigny P, Zhang L, El-Naggar AK, Papadimitrakopoulou V, Feng L, Lee J, Kim ES, Hong WK, Lippman SM, Mao L. Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial. Proc. of the Annual Meeting of the American Society of Clin. Oncology, Chicago, IL 28(15S):426s (#suppl; abstr 5521), 2010.
86. Papadimitrakopoulou V, Guo M, Etzel C, Solomon B, Sturgis EM, Lippman SM, Hong WK, Tsao AS. Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners. Proc. of the Annual Meeting of the Society of American Clin. Oncology, Chicago, IL 28(15S):427s (#suppl; abstr 5527), 2010.
87. Leighi NB, Soria J, Bennouna J, Blais N, TRaynor AM, Papadimitrakopoulou V, Klimovsky J, Jappe A, Jehl V, Johnson BE. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). Proc. of the Annual Meeting of the American Society of Clin. Oncology, Chicago, IL 28(15S):544s (#suppl; abstr 7524), 2010.
88. Yan W, Shih JH, Raso MG, Rodriguez-Canales J, Behrens C, Papadimitrakopoulou VA, Herbst RS, Emmett-Buck MR, Wistuba I, Erickson HS. Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodology. Proc of the 101th Annual Meeting of the American Association of Cancer Research, Washington, DC (#794), 2010.
89. Sano D, Matsumoto F, Valdecanas DR, Zhuo M, Molkentine DP, Papadimitrakopoulou V, Heymach JV, Raju U, Milas L, Myers JN. Treatment with vandetanib can overcome resistance of head and neck squamous cell carcinoma cells to cisplatin and radiation in an orthotopic animal model. Proc. of the 101th Annual Meeting of the American Association of Cancer Research, Washington DC (#369), 2010.
90. Chen N, Raben D, Frank S, Blumenschein GR, Kane M, Jimeno A, Langmuir P, Krebs, AD, Lippman SM, Papadimitrakopoulou V. Vandetanib with radiation therapy +/- cisplatin in previously untreated head and neck squamous cell carcinoma (HNSCC): Results from an ongoing phase I study. ASTRO Head and Neck Symposium, C Handler, AZ, 2010.
91. Papadimitrakopoulou V, Liu S, Fujimoto J, Wistuba I, Lee JJ, Maron EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein G, Kies M, Hong WK, Stewart DJ, Tsao A. Phase II trial of imatinib and docetaxel in patients with metastatic non-small cell lung cancer. Proc. of the 14th World Conference on Lung Cancer, 2011.
92. Ihle NT, Herbst RS, Kim ES, Wistuba II, Lee JJ, Blumenschein GR, Tsao AS, Chen L, Zhang S, Alden CM, Tang X, Liu S, Stewart DJ, Papadimitrakopoulou V, Heymach JV, Tran HT, Hicks ME, Erasmus JJ, Gupta S, Minna JD, Larsen J, Lippman SM, Hong WK, Powis G.

- Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer. Proc. of the 102th annual meeting of the American Association for Cancer Research, Orlando, FL 52:231 (#955), 2011.
93. Papadimitrakopoulou V, Heymach JV, Frank SJ, Myers JN, Lin HY, Tran HT, Chen C, Hirsch FR, Langmuir PB, Vasselli JR, Lippman SM, Raben D. Updated clinical and biomarker from a Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Proc of the Annual Meeting of the American Society of Clin. Oncology. Chicago, IL, 2011.
 94. Karp DD, Hammeken JM, Taylor SH, Men TY, Steinhaus G, Pisters K, Papadimitrakopoulou V. Young Women with non-squamous non-small cell lung cancer (NSCLC). J Thor Oncology 6(6S):S1408-S1408, 2011.
 95. Hong WK, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee JJ, Lippman S. Evolution of BATTLE trials at MD Anderson Cancer Center. Proc. of the 4th WIN Symposium on Efficacy of Biomarkers and Personalized Cancer Therapeutics, Paris, France. Ann Oncol 23(5):7-7, 2012.
 96. Saintigny P, Lang W, Jelinek J, Pickering CR, Feng L, Frederick ML, Zhang L, Ren H, Lee JJ, Kim ES, Fan YH, El-Naggar AK, Hong WK, Myers J, Papadimitrakopoulou VA, Issa JP, Lippman SM, Mao L. New DNA methylation markers associated with oral cancer (OC) development (dvlpt). Journal of Clinical Oncology (#suppl; abstr 5524), 2012.
 97. Papadimitrakopoulou VA, Wistuba II, Lee JJ, Tsao AS, Kalhor N, Fossella FV, Heymach J, Alden CM, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Davis SE, Powis G, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology (#suppl; abstr TPS8118), 10/2013.
 98. Tran HT, Melnikova VO, Tsao AS, Fossella FV, Johnson FM, Papadimitrakopoulou VA, Garza M, Neal C, Hasegawa, Kruempel A, Wu G, Richardson K, Lewis ME, Legendre BJ, Anderes KL, Davis DW, Heymach JV. Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream. Journal of Clinical Oncology (#suppl; abstr 11044), 10/2013.
 99. Tang X, Xue Y, Su X, Harun N, Cai Y, Behrens C, Papadimitrakopoulou VA, Blowers D, Moran C, Kalhor N, Rice DC, Beran G, Lee JJ, Kilgour E, Wistuba II. Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung. Journal of Clinical Oncology (#suppl; abstr 7552), 10/2013.
 100. Massarelli E, Ginsberg LE, Lin H, Tran HT, Lee JJ, Williams MD, Blumenschein GR, Lu C, Kies MS, Papadimitrakopoulou VA. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Journal of Clinical Oncology (#suppl; abstr 6067), 10/2013.
 101. Wakelee H, Soria J, Camidge R, Gadgeel SM, Goldman J, Varga A, Solomon B, Papadimitrakopoulou V, Kaur P, Sequist LV. First-In-Human Evaluation Of Co-1686, An Irreversible, Highly Selective Tyrosine Kinase Inhibitor Of Mutations Of Egfr (Activating And T790m). 2014 European Lung Cancer Conference, Geneva, Switzerland, 3/2014.
 102. Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou VA, Wistuba II, Goswami S, Cortez MA, Welsh J, Kurie JM, Heymach JV. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers. Journal of Clinical Oncology(32;5s) (#(suppl; abstr 3018)), 2014.
 103. Papadimitrakopoulou VA, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Heymach JV, Kalhor N, Gupta S, Gettinger SN, Byers LA, Izzo J, Miller VA, Diao L, Wang J, Wei C, Coombes KR, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATTLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology(32;5s) (#(suppl; abstr 8042)), 2014.
 104. Sequist LV, Soria JC, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, Solomon BJ, Papadimitrakopoulou VA, Jaw-Tsai SS, Caunt L, Kaur P, Rolfe L, Allen AR, Goldman JW. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). (32;5s) (#(suppl; abstr 8010^)), 2014.

105. William WN, Papadimitrakopoulou VA, Lee JJ, Mao L, Lin H, Gillenwater AM, Martin JW, Cohen EW, Lingen MW, Boyle J, Shin DM, Vigneswaran N, Shinn N, Myers J, El-Naggar AK, Lippman SM. Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). *Journal of Clinical Oncology*(32; 5s) (#(suppl; abstr 6007)), 2014.
106. Weidhaas JB, Kim ES, Herbst RS, J Yu, Slack F, Blumenschein GR, Tsao AS, Wistuba II, Lee JJ, Papadimitrakopoulou VA, Hong WK, Heymach JV, Tran HT. The KRAS-variant and treatment response in BATTLE-1. *Journal of Clinical Oncology*(32:5s) (#(suppl; abstr 8135)), 2014.
107. Sequist L, Goldman J, Wakelee H, Gadgeel S, Camidge R, Yu H, Varga A, Solomon B, Oxnard G, Ou SH, Papadimitrakopoulou V, Chao B, Liu SV, Reckamp K, Spira A, Piotrowska Z, Despaigne, Karlovich, Yurasov, Soria. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). *Journal of Clinical Oncology*, 5/2015.
108. Papadimitrakopoulou V, Patnaik A, Borghaei H, Stevenson J, Gandhi L, Gubens M, Yang CH, Sequist LV, Ge JY, Bourque J, Bachman RD, Im E, Gadgeel S. Phase 1 study of pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) in advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. *Journal of Clinical Oncology*, 5/2015.
109. Patnaik A, Gandhi L, Borghaei H, Socinski M, Gubens M, Stevenson J, Van Dam Sequist L, Yang CH, Papadimitrakopoulou V, Bourque J, Bachman RD, Yang Ge J, Im E, Gadgeel S. Phase 2 study of pembrolizumab (MK-3475) plus chemotherapy versus chemotherapy alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohort G1. *Journal of Clinical Oncology*, 6/2015.
110.  (b) (4)

Book Chapters

1. Papadimitrakopoulou V, Spiliotis I. Mediastinal tumors. In: *Clinical problems in surgery*. Voulgaris Editions: Greece, 83-88, 1989.
2. Papadimitrakopoulou V, Weber D. Multiple Myeloma and Other Plasma Cell Dyscrasias. In: *Medical Oncology. A Comprehensive Review*. PRR Huntington, New York, 127-38, 1995.
3. Papadimitrakopoulou V, Hong WK. Biology and Chemoprevention of Head and Neck Cancer. *Advances in Basic Research*. In: *Excerpta Medica International Congress Series 1114*. Ed(s) Werner JA, Lippert BM, Rudert HH (eds). Elsevier Science: Amsterdam, Netherlands, 613-28, 1996.
4. Papadimitrakopoulou V, Hong WK. Biomarkers as intermediate endpoints in chemoprevention trials-Biological basis of lung cancer prevention. In: *Clinical and Biological Basis of Lung Cancer Prevention*. Ed(s) Martinet Y, Hirsch FR, Martinet N, Vignaud JM and Mulshine J (eds). Birkhäuser Verlag: Switzerland, 305-11, 1997.
5. Papadimitrakopoulou V, Hong WK. A brief review of cancer chemoprevention. In: *Oncologic Therapies*. Ed(s) Vokes E, Golomb H (eds). Springer-Verlag, 1999.
6. Papadimitrakopoulou V, Hong WK. Head and Neck Cancer Chemoprevention. *Head and Neck Cancer*. In: *A Multidisciplinary Approach*. Ed(s) Harrison LB, Sessions RB, Hong WK (eds). Lippincott-Raven Publishers: Philadelphia, PA, 49-75, 1999.
7. Papadimitrakopoulou V, Hong KW. Molecular genetics of head and neck cancer: Implications for Cancer Chemoprevention. In: *Progress in Cancer Therapy, Vol II*. Ed(s) Khayat D, Hortobagyi GN. Blackwell Science, 191-205, 1999.
8. Papadimitrakopoulou V. A brief review of cancer chemoprevention. In: *Oncologic Therapies, 2nd Edition*. Ed(s) Vokes E, Golomb H (eds). Springer-Verlag: Berlin and Heidelberg, 2003.
9. Papadimitrakopoulou V, Hong WK. Chemoprevention. In: *Cancer of the Head and Neck, Fourth Edition*. Ed(s) Myers E, Hanna E, Myers J, Suen J (eds). WB Saunders, 737-46, 2003.

10. Papadimitrakopoulou V, Shin DM, Hong WK. Chemoprevention of Head and Neck Cancer. In: Head and Neck Cancer a Multidisciplinary Approach.. Ed(s) Harrison LB, Sessions RB, Hong WK (eds). Lippincott Williams & Wilkins, 985-1000, 2004.
11. Tsao A, Papadimitrakopoulou V. Chemoprevention of Head and Neck Cancer. In: Head and Neck Cancer: A Multidisciplinary Approach. Ed(s) Harrison LB, Sessions RB, Hong WK. Lippincott Williams & Wilkins, 918-934, 2009.
12. Papadimitrakopoulou, V. Novel Clinical Design Trial Designs for Metastatic Lung Cancer. In: Lung Cancer. Ed(s) Roth JA, Hong WK, Komaki RU. Wiley, 2013.

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Member, Editorial Board, Journal of Clinical Oncology, 2006-2009

Member, Editorial Board, Clinical Cancer Prevention, 2008-present

Member, Targeted Therapies in Oncology, 2013-present

Member of Editorial Review Board

Member, Clinical Cancer Prevention, 2008

Journal Reviewer

Reviewer, Journal of Thoracic Oncology, 2009

Reviewer, Oral Oncology, 2009

Biomarkers and Prevention

Cancer Letters

Cancer Research

Clinical Cancer Research

Head and Neck

International Journal of Cancer and Cancer Epidemiology

Journal of Clinical Oncology Methods in Molecular Biology

Other Editorial and Review Activities

Reviewer, 2009 ASCO Educational Book, 2009

Member, Frontiers in Cancer Prevention Research Conference, 2009

Reviewer, Genetics/Epigenetics of oral epithelial Dysplasia, Annual World workshop of Oral Medicine Proceedings, 2009

Reviewer, 2010 ASCO Educational Book, 2010

External Evaluator Research Proposals funded by the Greek State through the Ministry of Education, Life Long Learning and Religious Affairs, 2010

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

Lecturer, Novel Therapies for Head and Neck Cancer
2001

Instructor, Molecularly Targeted Prevention in Head and Neck Cancer, Division of
Medicine
2002

Lecturer, Novel Therapies for Head and Neck Cancer, MD Anderson Cancer Center
Medical Oncology Fellows
2002

Instructor, Targeted Prevention in Head and Neck Cancer
2003

Instructor, Chemoprevention of Head and Neck Cancer Surgery, Course Number:
Curriculum Series
2004

Didactic Lecturer, Chemoprevention of Upper Aerodigestive Tract Cancer, MD Anderson
Cancer Center Medical Oncology Fellows
2004

Lecturer, Dental Oncology Curriculum Series
2005-present

Lecturer, Clinical Testing of Supplements: Trials at The University of Texas MD Anderson
Cancer Center, Phase II of Green Tea
2005

Instructor, Head & Neck Surgery. Current Concepts in Head & Neck Surgery.
2005

Training Programs

N/A

Other Formal Teaching

N/A

**Supervisory Teaching
Committees**

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

 (b) (6)

Clinical Residents and Fellows

(b) (6)

Other Supervisory Teaching

Mentor, Mentoring Faculty Members
Mentor, Mentoring Faculty Members
Mentor, Mentoring Faculty Members
Mentor, Mentoring Faculty Members

(b) (6)

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Lecturer, 1st Scientific Symposium “New Perspectives in Cancer Treatment,” New Targeted Therapies in Lung Cancer,” Thessaloniki, Greece
1998

Lecturer, Post Graduate Seminar in Oncology, Prevention of Upper Aerodigestive Tract Cancer & Biomarkers of Upon Aerodigestive Tract Carcinogenesis, Jeraklion, Creta, Greece
2002

Lecturer, Prevention of Upper Aerodigestive Tract Malignancies, AAO-HNSF. Annual Meeting. Early Detection of Head and Neck Cancer, San Diego, CA, AAO-HNSF
2002

Lecturer, Chemoprevention of Head and Neck Cancer. International Symposium on Dietary Factors and Cancer Prevention: Current Premises and Future Promises., Rochester, MN
2004

Lecturer, Head and Neck Cancer Chemoprevention, 9th Annual Oncology Conference, Lake of the Ozarks, MI
2004

Chair at NSCLC Session/Course Organizer, Workshop MDACC Physicians Network. Second Annual Symposium, Kauai, HI
2006

Lecturer, Continuing Medical Education Series Emerging Therapies for Head and Neck Cancer. An Educational Meeting Series, Chicago and New York
2010

Lecturer, Continuing Medical Education Series Management of Adverse Events Associated with EGFR-inhibitor Therapy, Dallas, Texas
2010

Lecturer, EGFR Inhibitors in Head and Neck Cancer, Sixth Annual Oncology Congress, San Francisco, CA
2010

Expert Advisor, Staging Risk Stratification and prognostication in early stage NSCLC, University of Nebraska Medical Center in Houston, Texas
2010

Lecturer, Best of ASCO 2012 China, Chinese Society of Clinical Oncology
2012

Lecturer, Novel targets for lung cancer: How close are we?, Best of ASCO 2012 China Lung Cancer Session, Chinese Society of Clinical Oncology
2012

Lecturer, Strategy for research on lung cancer, Best of ASCO 2012, China Lung Cancer Session, Chinese Society of Clinical Oncology
2012

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

(b) (6)

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

American Society of Clinical Oncology (ASCO), 2005 ASCO Scientific Program Committee, Orlando, FL, Member, 5/2005

American Society of Clinical Oncology (ASCO), Annual Meeting 2006, Atlanta, GA, Chair, 6/2006

American Society of Clinical Oncology (ASCO), 2007 Annual Meeting Session Chair Prevention. Session: Highlights of the Day, Chicago, IL, Lecturer, 6/2007

American Society of Clinical Oncology (ASCO), ASCO Cancer Education Committee: Head and Neck Track, Member, 2009

American Association for Cancer Research (AACR), 2009 AACR Program Committee: Preclinical Prevention Studies Subcommittee of the Prevention Research Section, Denver, CO, Chair, 4/2009

American Society of Clinical Oncology (ASCO), ASCO 45th Annual Meeting, Head and Neck Cancer Poster. Discussion Session, Orlando, FL, Co-Chair, 6/2009

American Society of Clinical Oncology (ASCO), Educational Committee, Head and Neck Track, Chair, 2010

American Society of Clinical Oncology (ASCO), Scientific Committee, Head and Neck Cancer Track, Member, 2010

Cancer Advance Boston: Focus on Innovation, Boston, MA, Moderator, 9/2014

Hellenic Oncology Research Group: 3rd Annual Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, Moderator, 2/2015

Hellenic Research Group: 3rd Annual Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, Chair, 2/2015

Presentations at National or International Conferences

Invited

Papadimitrakopoulou V, Shin DM, Clayman G, El Naggar A, Martinez L, Gillenwater A, Goepfert H, Hong WK. Biochemoprevention or advanced premalignant lesions in the upper aerodigestive tract, Seventh International Congress on anti-cancer treatments, Paris, France, 2/3/1997

Efficacy of Biochemoprevention in Reversal of Advanced Premalignant Lesions of the Upper Aerodigestive Tract, 33rd Annual Meeting of the ASCO, Denver, CO, 5/1/1997

Biochemoprevention for Advanced Premalignant Lesions of the Upper Aerodigestive Tract, International Conference of the International Society of Differentiation, Houston, TX, 10/1/1998

Multiple mechanisms of p16 inactivation in advanced premalignant lesions (APL) of the upper aerodigestive tract (UADT), 91st Annual Meeting of the AACR, San Francisco, CA, 4/1/2000

Frequent and Early Alterations in B-Catenin Expression during Head and Neck Tumorigenesis, 92nd Annual Meeting of the American Association of Cancer Research, New Orleans, LA, 3/1/2001

Papadimitrakopoulou VA. Methods in Clinical Care, 3rd FECS AACR ASCO Workshop Methods in Clinical Ca, Flims, Switzerland, 6/1/2001

Chemoprevention Trials in Head and Neck Cancer, Head and Neck Intergroup Meeting, Rockville, MD, 12/1/2001

Other EGFR inhibitors: PKI-166, 2nd Annual Opinion Leader Summit, "Targeted Therapies in the Treatment of Lung Cancer," , Scottsdale, AZ, 2/1/2002

IGFBP3 Loss Predicts for Adverse Outcome in Head and Neck Squamous Cell Carcinoma, 94th Annual Meeting of American Association of Cancer Research, Washington, DC, 6/1/2002

Predictive Role of p27 Loss of Protein Expression Alone and In Association with Loss of E-cadherin Protein Expression in Preneoplastic Lesions of Head and Neck, 94th Annual Meeting of American Association of Cancer Research, Washington, DC, 6/1/2002

Prevention of Upper Aerodigestive Tract Malignancies, AAO-HNSF, Annual Meeting, Early Detection of Head and Neck Cancer, San Diego, CA, 9/1/2002

TLK286 Trials NSCLC, 3rd Annual Opinion Leader Summit, "Targeted Therapies in the Treatment of Lung Cancer," , Aspen, CO, 1/1/2003

Molecularly Targeted Chemoprevention of Head and Neck Cancer, 94th Annual Meeting American Association of Cancer, Washington, DC, 7/1/2003

Development of TLK286 for Non-Small Cell Lung Cancer, 2004 Targeted Therapies for the Treatment of Lung Cancer Investigator's Meeting, San Diego, CA, 2/1/2004

Overview of Chemoprevention in Head & Neck Cancer - Molecular Screening and Risk Prediction, 2nd Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck Cancer, Montego Bay, Jamaica, 2/1/2004

Head and Neck Cancer Workshop, National Cancer Institute, Washington, DC, 5/1/2004

TLK286, 5th International Lung Cancer Congress, Kauai, HI, 7/1/2004

mTOR Inhibitors in Lung Cancer, 5th Annual Targeted Therapies for the Treatment of Lung Cancer, Steamboat Springs, CO, 2/1/2005

Oral Cancer, 10th International Congress on Oral Cancer, Greece, 4/1/2005

mTOR Inhibitors for NSCLC, 6th Annual Targeted Treatment of Lung Cancer, Santa Monica, CA, 1/20/2006

Head & Neck Cancer, 4th Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head, Neck Cancer, Biscayne, FL, 2/1/2006

Cancer Prevention, NCI Workshop Imaging Science Development for Cancer Prevention and Preemption, Gaithersburg, MD, 7/20/2006

Head & Neck Cancer, 4th International Chicago Symposium on Malignancies of the Chest, Head & Neck, Chicago, IL, 10/1/2006

Head & Neck Cancer, Second Annual Head and Neck Cancer Symposium, Philadelphia, PA, 10/1/2006

Cancer Prevention, 5th Annual AACR International Conference Frontiers in Cancer Prevention Research, Boston, MA, 11/1/2006

A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy © or prior C and EGFR inhibitors (EDFR-I). C1: Molecular Targeted Therapy: Beyond EGFR., Oral presentation at 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, Korea, Republic of, 2007

Diagnosis & Therapy. Genetics, Advances and Challenges in Aerodigestive Epithelial Cancer, Charleston, SC, 2/1/2007

Identification of High Risk Cohorts for Head and Neck Cancer Prevention Based on Tissue Markers, ASCO Annual Meeting, Chicago, IL, 1/6/2008

Rad001 Update, 8th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA, 2/21/2008

Papadimitrakopoulou. Erlotinib prevention of oral cancer (EPOC), MD Anderson Cancer Center | IGR Workshop, Institute Gustave Roussy, Houston, TX, 4/11/2008

Chemoprevention in the Era of Personalized Medicine, Recent Advances, AACR Annual meeting Session, San Diego, CA, 4/20/2008

Early Development in Oncology, Novartis Oncology LEAD Summit VI, Montreal, Quebec, Canada, 6/21/2008

Oral Epithelial Dysplasia, American Academy of Oral and Maxillofacial Pathology, San Francisco, CA, 6/24/2008

Oral Epithelial Dysplasia, 90th AAOMS/AAOMP Annual Meeting, American Academy of Oral and Maxillofacial Pathology, San Francisco, CA, 6/24/2008

Targeted Therapy-Angiogenesis Inhibition, Lunch with the Professors, 7th International Conference on Head and Neck Cancer, San Francisco, CA, 7/1/2008

Targeting EGFR Signaling in High-Risk Oral Intraepithelial Neoplasia, 7th International Conference on Head and Neck Cancer, San Francisco, CA, 7/1/2008

Head and Neck Cancer, Third Hellenic Forum of Oncology, Crete, Greece, 7/4/2008

Bridging Prevention and Treatment for Cancer of the Upper Aerodigestive Tract: Molecular Targeting, Department of Cancer Medicine Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, 12/3/2008

RAD001 Everolimus alone + with CT, 9th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA, 2/18/2009

Everolimus and Erlotinib, 10th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2010

AZD6244 + MK2206, 11th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2011

AZD6244 + MK2206, 12th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2012

Working Group Member: Design of a Disease-specific Master Protocol.. Conference on Clinical Cancer Research, Engelbert Center for the Health Care Reform, ASCO, AACR, Susan G. Komen for the Cure, Washington, DC, 11/14/2012

Co-Chair. Personalizing Lung Cancer Therapy-The BATTLE Program, MDACC, Transatlantic Science Week Sister Institution Network, Houston, TX, 11/15/2012

Treatment of Thoracic and head and Neck Malignancies: A Personal Journey with a View at Novel Concepts, Grand Rounds, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 11/16/2012

A2D4547, 13th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2013

MK 2206 + AZD 6244, 13th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2013

Personalizing NSCLC Therapy: BATTLE-2 Program, Molecular Med Tri-Con, San Francisco, CA, 2/11/2013

Personalizing Therapy in NSCLC: the BATTLE programs, 2nd International Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 4/4/2013

Personalizing therapy in NSCLC: the BATTLE programs, 2nd International Symposium on Thoracic and Upper Aerodigestive Malignancies, Hellenic Society of Medical Oncology (HeSMO), Athens, Greece, 4/6/2013

Papadimitrakopoulou V. "Master protocols for squamous carcinoma," 6th International Conference on Molecular Targeted Therapy in Lung Cancer, Sorrento, Italy, 4/17/2013

Papadimitrakopoulou V. Master protocol for squamous carcinoma, Lung SPORE Workshop, Rockville, MD, 7/10/2013

Papadimitrakopoulou V. Targeting the PI3K/AKT Axis: Picking a Winner, Physician Education Resource LLC, 14th International Lung Cancer Congress, Huntington Beach, CA, 7/25/2013

Papadimitrakopoulou VA. Oral Discussant, 15th World Conference on Lung Cancer, International Association for Study of Lung Cancer, Sydney, Australia, 10/2013

Papadimitrakopoulou V, Wistuba I, Lee JJ, Tsao AS, Kalhor N, Fossella F, Heymach JV, White A, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Caimiao W, Powis G, Mauro DJ, Rubiin EH, Hong W, Herbst R. BATTLE - 2 Program: A Biomarker - Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non - Small Cell Lung Cancer (NSCLC), International Association for the Study of Lung Cancer, Sydney, Australia, 10/29/2013

Papadimitrakopoulou V, Gandara D, Hirsch F, Sigal E, Redman M, Allen J, Mack P, Wistuba I, Herbst R. Phase II/III Biomarker - Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (SCCA), International Association for the Study of Lung Cancer, Sydney, Australia, 10/29/2013

Papadimitrakopoulou V. Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer, Cambridge Healthtech Institute, Molecular Med Tricon 2014: 10th Annual Clinical Translational Science Meeting, San Francisco, CA, 2/12/2014

Papadimitrakopoulou V. AZD 4547, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/20/2014

Papadimitrakopoulou V. Master Protocol, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/21/2014

Papadimitrakopoulou V. MK 2206 + AZD 6244, IASLC, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/22/2014

Papadimitrakopoulou V. Head & Neck Cancer, Oral Abstract Presentation, ASCO Annual Meeting 2014, ASCO, Chicago, IL, 6/2/2014

Papadimitrakopoulou VA. Response kinetics and modified RECIST with Immune Therapies, Physician Education Resources LLC, 15th Annual International Lung Cancer Congress, Huntington Beach, CA, 8/1/2014

Papadimitrakopoulou VA, Gandara D, Hirsch F, Redman M, Herbst R. PHASE II/III biomarker-driven Master Protocol for second line, Physician Education Resources LLC (PER), 15th Annual International Lung Cancer Congress, Huntington Beach, CA, 8/2/2014

Papadimitrakopoulou VA. Lung Master Protocol, a Phase II/III Study for Second Line Therapy of Advanced Squamous Lung Carcinoma Re-thinking clinical trial design for NSCLC, The US Oncology Network 13th Annual Science Forum, Grapevine, TX, 9/19/2014

Papadimitrakopoulou VA. Lung Master Protocol, a Phase II/III Study for Second Line Therapy of Advanced Squamous Lung Carcinoma Re-thinking clinical trial design for NSCLC, Southwest Oncology Group, Jeri & Noboru Oishi Symposium, Chicago, IL, 10/23/2014

Papadimitrakopoulou VA. Oral Discussant, ASCO, ASTRO, IASLC, University of Chicago, 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, 10/31/2014

Papadimitrakopoulou VA. Master Protocol for Previously Treated Squamous Cell Carcinoma, ASCO, ASTRO, IASLC, University of Chicago, 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, 11/1/2014

Papadimitrakopoulou VA. Molecular Landscapes in Lung Cancer: Landscape in the USA, Hellenic Oncology Research Group, 3rd Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 2/7/2015

Papadimitrakopoulou VA. Round Table: Emerging Targeted Therapies in NSCLC: Targeted Therapies for Squamous Cell NSCLC, Hellenic Oncology Research Group, 3rd Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 2/7/2015

Papadimitrakopoulou VA. EGFR: 3rd Generation: AC 001 MA, International Association of the Study of Lung Cancer (IASLC): 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/19/2015

Papadimitrakopoulou VA. MEK/AKT/KRAS: MK 2206 (AKT), International Association of the Study of Lung Cancer (IASLC): 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/20/2015

Papadimitrakopoulou VA. FGFR +/- VEGFR, PDGFR/Angiogenesis: AZD 4547, International Association of the Study of Lung Cancer (IASLC): 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/21/2015

Papadimitrakopoulou VA. Current ECOG, CALGB and SWOG Clinical Trials, Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer and Breast Cancer, CancerNet, Houston, TX, 4/3/2015

(b) (4)

Other, Including Scientific Exhibitions

N/A

Seminar Invitations from Other Institutions

The Path of Women Who Lead, Third WICR Leadership Development Workshop, American Association of Cancer Research, San Diego, CA, 4/12/2008

Molecularly Targeted Therapies and Prevention Approaches for Upper Aerodigestive Tract Cancer, University of Miami/Sylvester Comprehensive Cancer, 3/2009

Oncology meets Immunology, European Thoracic Oncology Platform, Oncology Center of Biomedical Education and Research, Oncology Unit, Athens School of Medicine, Athens, Greece, Greece, 6/2015

Evolving Role of Immunotherapy in Lung Cancer, 11th Annual MD Anderson-Physicians network Symposium, National Harbor, MD, 7/2015

Lectureships and Visiting Professorships

Grand Rounds: The Julia and Patricia Kinsbury Lecture, Yale Cancer Center, New Haven, CT, 6/19/2012

Lung Cancer Therapy: A view of current and novel concepts, Winship Cancer Institute of Emory University, Atlanta, GA, 9/1/2012

Grand Rounds, Lung Cancer Therapy: A view of current and novel concepts, Vanderbilt University, Nashville, TN, 10/3/2012

Precision Medicine for NSCLC in the Era of Genomic Profiling and Immunotherapy; Rethinking Trial Designs and Translational Endpoints., Deans Distinguished Lecture Series, Cornell University, Cancer Medicine, New York, NY, 12/12/2014

Other Presentations at State and Local Conferences

Papadimitrakopoulou VA. Personalizing Lung Cancer Therapy: The Paradigm and Vision of the Future, Division of Cancer Medicine Grand Rounds, MD Anderson Cancer Center, Houston, TX, 2/24/2015

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

International Association for the Study of Lung Cancer

Member, 2003-present

Membership Committee Member, 2013

American Society of Clinical Oncology (ASCO)

Member, 2007-present

AACR Program Committee Subcommittee, Philadelphia, PA

Chair, 2008-present

American Association for Cancer Research (AACR)

Program Committee Chairperson (Prevention), 2009

American Society of Clinical Oncology (ASCO)

Member, Scientific Program Committee, 2009-2015

Chair, Scientific Committee, 2010

American Society of Clinical Oncology (ASCO)

Member, ASCO Educational Book, 2009

American Society of Clinical Oncology (ASCO)

Member, Cancer Education Committee, 2009

Southwest Oncology Group (SWOG)

Member, Lung Committee, 2011-present

Friends of Cancer Research & Engelberg Center for Health Care Reform at Brookings, DC

Panelist, 2013

American Association for the Advancement of Science

Local/State

N/A

UNIQUE ACTIVITIES

1. Steering Committees & National Projects

Leader Steering Committee and Drug Selection Committee: Master Lung Protocol

Principal Investigator, Master Lung Protocol (a project sponsored by SWOG, Friends of Cancer Research, Foundation for the National Institutes of Health, Federal Drug Administration, & National Cancer Institute, 2013

APPEARS THIS WAY ON
ORIGINAL.

2. Steering Committee –Global Principal Investigator A Phase III Open Label, Randomized Study of AZD9291 versus Platinum Based Doublet Chemotherapy for patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbor a T790M mutation within the EGFR gene (AURA3).

DATE OF LAST CV UPDATE

5/6/2015